Organometallic compound, organic light-emitting device comprising the same, and diagnostic composition comprising the same

Abstract

Provided are an organic metal compound, an organic light-emitting device comprising the same, and a diagnostic composition comprising the organic metal compound. The organic metal compound is represented by Formula 1A, wherein in Formula 1A, each group and each variable are as described in the specification.

Description

[0001] This application is a divisional application of the invention application with the application date of July 5, 2017, the Chinese application number of 201710541197.3, and the invention name of “Organometallic compounds, organic light-emitting devices including the same, and diagnostic compositions including the organometallic compounds”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of Korean Patent Application No. 10-2016-0085069, filed on Jul. 5, 2016, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference. Technical Field

[0004] One or more embodiments are directed to an organometallic compound, an organic light emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound. Background Art

[0005] The organic light emitting device is a self-emitting device that has excellent characteristics in terms of viewing angle, response time, brightness, driving voltage, and response speed and produces a full-color image.

[0006] In one example, an organic light emitting device includes an anode, a cathode, and an organic layer between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be between the anode and the emission layer, and an electron transport region may be between the emission layer and the cathode. Holes provided by the anode may move toward the emission layer through the hole transport region, and electrons provided by the cathode may move toward the emission layer through the electron transport region. Holes and electrons recombine in the emission layer to generate excitons. These excitons transition from an excited state to a ground state, thereby generating light.

[0007] Meanwhile, the luminescent compound can be used to monitor, sense, or detect a variety of biological materials, including cells and proteins. Examples of the luminescent compound include phosphorescent luminescent compounds. Summary of the invention

[0008] One or more embodiments include novel organometallic compounds, organic light emitting devices including the organometallic compounds, and diagnostic compositions including the organometallic compounds.

[0009] Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

[0010] According to one or more embodiments, the organometallic compound is represented by Formula 1A:

[0011] <Formula 1A>

[0012]

[0013] In Formula 1A,

[0014] M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt) or gold (Au),

[0015] X 1 Can be O or S, in X 1 The bond between and M may be a covalent bond,

[0016] X 2 and X 3 can be independently C or N,

[0017] X 4 Can be N,

[0018] Selected from X 2 The key between X 3 and M, and the key between X 4 One of the bonds between and M may be a covalent bond, and the others thereof may each be a coordinate bond,

[0019] Y 1 and Y 3 -Y 5 can be independently C or N,

[0020] In X 2 and Y 3 The key between X 2 and Y 4 The key between 4 and Y 5 The key between 5 and X 51 The key between X 51 and Y 3 The bonds between them can each be chemical bonds,

[0021] CY 1 -CY 5 Can be independently selected from C 5 -C 30 Carbocyclic groups and C 1 -C 30 Heterocyclic group, wherein CY 4 Not a benzimidazole group,

[0022] By CY 5 CY2 CY 3 The cyclometallated ring formed with M may be a 6-membered ring,

[0023] X 51 Can be selected from O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 )、C(=O)、N、C(R 7 )、Si(R 7 ) and Ge(R 7 ),

[0024] R 7 and R 8 Can be optionally linked via a first linking group to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0025] L 1 -L 4 and L 7 may be independently selected from substituted or unsubstituted C 5 -C 30 Carbocyclic groups and substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0026] b1-b4 and b7 can each independently be an integer of 0-5,

[0027] R 1 -R 4 , R 7 and R 8 can be independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, -SF 5 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, substituted or unsubstituted C 1 -C 60 Alkyl, substituted or unsubstituted C 2 -C 60 Alkenyl, substituted or unsubstituted C 2 -C 60 Alkynyl, substituted or unsubstituted C1 -C 60 Alkoxy, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 6 -C 60 Aryloxy, substituted or unsubstituted C 6 -C 60 Arylthio, substituted or unsubstituted C 1 -C 60 heteroaryl, a substituted or unsubstituted monovalent non-aromatic fused polycyclic group, a substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ),

[0028] c1-c4 can each independently be an integer of 1-5,

[0029] a1-a4 can each independently be 0, 1, 2, 3, 4 or 5,

[0030] Multiple adjacent R 1 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0031] Multiple adjacent R 2 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0032] Multiple adjacent R 3 Two of may be optionally linked to form a substituted or unsubstituted C5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0033] Multiple adjacent R 4 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0034] Selected from R 1 -R 4 Two or more adjacent groups of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0035] In the following cases, a1-a4 can each independently be 1, 2, 3, 4 or 5 and are selected from R 1 -R 4 At least one of which may be selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 1 -C 60 heteroaryl, substituted or unsubstituted monovalent non-aromatic fused polycyclic group, and substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group: wherein i) M is Pt, ii) X 1 O, iii)X 2 and X 4 Each is N, X 3 For C, in X 2 and M and the bond between X 4 The bonds between X and M are each coordination bonds, and 3 The bond between Y and M is a covalent bond, iv) 1 and Y 3 -Y 5 Each is C, v) in Y 5 and X 51The key between 3 and X 51 The bonds between are each single bonds, vi)CY 1 CY 2 and CY 3 Each is a phenyl group, and CY 4 is a pyridine group, vii) X 51 O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ], and viii) b7 is 0, c7 is 1, and R 7 is substituted or unsubstituted C 1 -C 60 alkyl,

[0036] The substituted C 5 -C 30 Carbocyclic groups, substituted C 1 -C 30 Heterocyclic groups, substituted C 1 -C 60 Alkyl, substituted C 2 -C 60 Alkenyl, substituted C 2 -C 60 Alkynyl, substituted C 1 -C 60 Alkoxy, substituted C 3 -C 10 Cycloalkyl, substituted C 1 -C 10 Heterocycloalkyl, substituted C 3 -C 10 Cycloalkenyl, substituted C 1 -C 10 Heterocycloalkenyl, substituted C 6 -C 60 Aryl, substituted C 6 -C 60 Aryloxy, substituted C 6 -C 60 Arylthio, substituted C 1 -C 60 At least one substituent of the heteroaryl group, the substituted monovalent non-aromatic fused polycyclic group, and the substituted monovalent non-aromatic fused heteropolycyclic group may be selected from:

[0037] Deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy;

[0038] Each of the following is substituted by at least one C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 11 )(Q 12 )、-Si(Q 13 )(Q 14 )(Q 15 )、-B(Q 16 )(Q 17 ) and -P(=O)(Q 18 )(Q 19 );

[0039] C3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups;

[0040] Each of the following is substituted by at least one C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 Heteroaryl, monovalent non-aromatic fused polycyclic group, and monovalent non-aromatic fused heteropolycyclic group: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 21 )(Q 22 )、-Si(Q 23 )(Q 24 )(Q 25 )、-B(Q 26 )(Q 27 ) and -P(=O)(Q 28 )(Q 29 );and

[0041] -N(Q 31 )(Q 32 )、-Si(Q 33 )(Q 34 )(Q 35 )、-B(Q 36 )(Q 37 ) and -P(=O)(Q 38 )(Q 39 ),and

[0042] Q 1 -Q 9 , Q 11 -Q 19 , Q 21 -Q 29 and Q 31 -Q 39 can be independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 60 Alkyl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups.

[0043] According to one or more embodiments, an organic light emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer and including at least one of the organic metal compounds.

[0044] The organometallic compound may serve as a dopant in the organic layer.

[0045] According to one or more embodiments, the diagnostic composition includes at least one of the organometallic compounds represented by Formula 1A.

[0046] The object of the present invention is achieved by the following items:

[0047] 1. An organometallic compound represented by Formula 1A:

[0048] <Formula 1A>

[0049]

[0050] Wherein, in Formula 1A,

[0051] M is beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt) or gold (Au),

[0052] X 1is O or S, and in X 1 The bond between M and is a covalent bond.

[0053] X 2 and X 3 are each independently C or N,

[0054] X 4 For N,

[0055] Selected from X 2 The key between X 3 and M, and the key between X 4 One of the bonds between and M is a covalent bond, and the others are each coordinate bonds,

[0056] Y 1 and Y 3 -Y 5 are each independently C or N,

[0057] In X 2 and Y 3 The key between X 2 and Y 4 The key between 4 and Y 5 The key between 5 and X 51 The key between X 51 and Y 3 The bonds between them are chemical bonds.

[0058] CY 1 -CY 5 Each independently selected from C 5 -C 30 Carbocyclic groups and C 1 -C 30 Heterocyclic group, wherein CY 4 Not a benzimidazole group,

[0059] By CY 5 CY 2 CY 3 The cyclometallated ring formed with M is a 6-membered ring,

[0060] X 51 Selected from O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8)、C(=O)、N、C(R 7 )、Si(R 7 ) and Ge(R 7 ),

[0061] R 7 and R 8 Optionally connected via a first linking group to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0062] L 1 -L 4 and L 7 are each independently selected from substituted or unsubstituted C 5 -C 30 Carbocyclic groups and substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0063] b1-b4 and b7 are each independently an integer of 0-5,

[0064] R 1 -R 4 , R 7 and R 8 Each independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, -SF 5 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, substituted or unsubstituted C 1 -C 60 Alkyl, substituted or unsubstituted C 2 -C 60 Alkenyl, substituted or unsubstituted C 2 -C 60 Alkynyl, substituted or unsubstituted C 1 -C 60 Alkoxy, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 6 -C 60 Aryloxy, substituted or unsubstituted C6 -C 60 Arylthio, substituted or unsubstituted C 1 -C 60 heteroaryl, a substituted or unsubstituted monovalent non-aromatic fused polycyclic group, a substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ),

[0065] c1-c4 are each independently an integer of 1-5,

[0066] a1-a4 are each independently 0, 1, 2, 3, 4 or 5,

[0067] Multiple adjacent R 1 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0068] Multiple adjacent R 2 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0069] Multiple adjacent R 3 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0070] Multiple adjacent R 4 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0071] Selected from R 1 -R 4Two or more adjacent groups of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0072] In the following cases, a1-a4 are each independently 1, 2, 3, 4 or 5 and are selected from R 1 -R 4 At least one selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 1 -C 60 heteroaryl, substituted or unsubstituted monovalent non-aromatic fused polycyclic group, and substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group: wherein i) M is Pt, ii) X 1 O, iii)X 2 and X 4 Each is N, X 3 For C, in X 2 and M and the bond between X 4 The bonds between X and M are each coordination bonds, and 3 The bond between Y and M is a covalent bond, iv) 1 and Y 3 -Y 5 Each is C, v) in Y 5 and X 51 The key between 3 and X 51 The bonds between are each single bonds, vi)CY 1 CY 2 and CY 3 Each is a phenyl group and CY 4 is a pyridine group, vii) X 51 O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ], and viii) b7 is 0, c7 is 1, and R 7 is substituted or unsubstituted C 1 -C60 alkyl,

[0073] The substituted C 5 -C 30 Carbocyclic groups, substituted C 1 -C 30 Heterocyclic groups, substituted C 1 -C 60 Alkyl, substituted C 2 -C 60 Alkenyl, substituted C 2 -C 60 Alkynyl, substituted C 1 -C 60 Alkoxy, substituted C 3 -C 10 Cycloalkyl, substituted C 1 -C 10 Heterocycloalkyl, substituted C 3 -C 10 Cycloalkenyl, substituted C 1 -C 10 Heterocycloalkenyl, substituted C 6 -C 60 Aryl, substituted C 6 -C 60 Aryloxy, substituted C 6 -C 60 Arylthio, substituted C 1 -C 60 At least one substituent of the heteroaryl group, the substituted monovalent non-aromatic fused polycyclic group, and the substituted monovalent non-aromatic fused heteropolycyclic group is selected from:

[0074] Deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy;

[0075] Each of the following is substituted by at least one C 1 -C 60 Alkyl, C 2 -C60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 11 )(Q 12 )、-Si(Q 13 )(Q 14 )(Q 15 )、-B(Q 16 )(Q 17 ) and -P(=O)(Q 18 )(Q 19 );

[0076] C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups;

[0077] Each of the following is substituted by at least one C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 Heteroaryl, monovalent non-aromatic fused polycyclic group, and monovalent non-aromatic fused heteropolycyclic group: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 21 )(Q 22 )、-Si(Q 23 )(Q24 )(Q 25 )、-B(Q 26 )(Q 27 ) and -P(=O)(Q 28 )(Q 29 );and

[0078] -N(Q 31 )(Q 32 )、-Si(Q 33 )(Q 34 )(Q 35 )、-B(Q 36 )(Q 37 ) and -P(=O)(Q 38 )(Q 39 ),and

[0079] Q 1 -Q 9 , Q 11 -Q 19 , Q 21 -Q 29 and Q 31 -Q 39 are each independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amidino, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 60 Alkyl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 6 -C60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups.

[0080] 2. The organometallic compound as described in item 1, wherein CY 1 -CY 4 are each independently selected from a) a 6-membered ring, b) a condensed ring having two or more 6-membered rings fused to each other, and c) a condensed ring having one 5-membered ring and two or more 6-membered rings fused to each other,

[0081] wherein the 6-membered ring is selected from a cyclohexane group, a cyclohexene group, an adamantane group, a norbornane group, a norbornene group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group and a triazine group, and

[0082] The 5-membered ring is selected from a cyclopentane group, a cyclopentene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole groups and thiadiazole groups.

[0083] 3. The organometallic compound as described in item 1, wherein CY 1 -CY 4 Each is independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a benzo[9,10]phenanthrene group, a pyrene group, group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a fluorene group, a carbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a 5,6,7,8-tetrahydroisoquinoline group, a 5,6,7,8-tetrahydroquinoline group, a 5,6,7,8-tetrahydrophthalazine group, and a 5,6,7,8-tetrahydrocinnoline group.

[0084] 4. The organometallic compound according to item 1, wherein R 1 -R 4 , R 7 and R 8 Each independently selected from:

[0085] hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, -SF 5 , C 1 -C 20 Alkyl and C 1 -C 20 Alkoxy;

[0086] Each of the following is substituted by at least one C 1 -C 20 Alkyl and C 1 -C 20 Alkoxy: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl;

[0087] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl;

[0088] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33)(Q 34 )(Q 35 );and

[0089] -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ),and

[0090] Q 1 -Q 9 and Q 33 -Q 35 Each independently selected from:

[0091] -CH 3 、-CD 3 、-CD 2 H.-CDH 2 、-CH 2 CH 3 、-CH 2 CD 3 、-CH 2 CD 2 H, -CH 2 CDH 2 、-CHDCH 3 、-CHDCD 2 H, -CHDCDH 2 、-CHDCD 3 、-CD 2 CD 3 、-CD 2 CD 2 H and -CD 2 CDH 2 ;

[0092] n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl, and naphthyl; and

[0093] each of which is selected from at least one substituted n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl and naphthyl: deuterium, C 1 -C 10 Alkyl and phenyl.

[0094] 5. The organometallic compound according to item 1, wherein R 1 -R 4 , R7 and R 8 are each independently selected from hydrogen, deuterium, -F, cyano, nitro, -SF 5 、-CH 3 、-CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , -C 2 F 5 , -C 2 F 4 H, -C 2 F 3 H 2 , -C 2 F 2 H 3 , -C 2 FH 4 , groups represented by formulae 9-1 to 9-19, groups represented by formulae 10-1 to 10-167, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ):

[0095]

[0096]

[0097]

[0098]

[0099] Q 1 -Q 9 Each independently selected from:

[0100] -CH 3 、-CD 3 、-CD 2 H.-CDH 2 、-CH 2 CH 3 、-CH 2 CD 3 、-CH 2 CD 2 H, -CH 2 CDH2 、-CHDCH 3 、-CHDCD 2 H, -CHDCDH 2 、-CHDCD 3 、-CD 2 CD 3 、-CD 2 CD 2 H and -CD 2 CDH 2 ;

[0101] n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl, and naphthyl; and

[0102] each of which is selected from at least one substituted n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl and naphthyl: deuterium, C 1 -C 10 Alkyl and phenyl, and

[0103] In equations 9-1 to 9-19 and 10-1 to 10-167,

[0104] * indicates the binding site to the neighboring atom;

[0105] Ph represents phenyl; and

[0106] TMS stands for trimethylsilyl.

[0107] 6. The organometallic compound according to item 1, wherein a1-a4 are each independently 1, 2, 3, 4 or 5, and

[0108] i) selected from R 1 -R 4 At least one of them is not hydrogen,

[0109] ii) selected from R 1 , R 2 and R 4 At least one of them is not hydrogen,

[0110] iii) selected from R 1 -R 3 At least one of is not hydrogen, or

[0111] iv) selected from R 1 and R 2 At least one of them is not hydrogen.

[0112] 7. The organometallic compound according to item 1, wherein

[0113] i) In Y 3and X 51 The key between 5 and X 51 Each bond between is a single bond, and X 51 C(R 7 )(R 8 )、Si(R 7 )(R 8 ), or C(=O),

[0114] ii) In Y 3 and X 51 The key between 5 and X 51 The bonds between them are single bonds, X 51 N-[(L 7 ) b7 -(R 7 ) c7 ], and R 7 is selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 6 -C 60 Aryloxy, substituted or unsubstituted C 6 -C 60 Arylthio, substituted or unsubstituted C 1 -C 60 heteroaryl, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, or

[0115] iii) selected from Y 3 and X 51 The key between 5 and X 51 One of the bonds between is a single bond and the other is a double bond, and X 51 N, C (R 7 ), or Si(R 7 ).

[0116] 8. The organometallic compound according to item 1, wherein X 51 O, S, or N-[(L 7 ) b7 -(R7 ) c7 ],

[0117] b7 is 0,

[0118] c7 is 1,

[0119] R 7 Selected from:

[0120] C 1 -C 30 Alkyl; and

[0121] C substituted by at least one selected from the following 1 -C 30 Alkyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, C 1 -C 10 alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl,

[0122] a1-a4 are each independently 1, 2, 3 or 4,

[0123] Selected from R 1 -R 4 At least one of each is independently selected from:

[0124] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazineyl, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, and imidazopyrimidinyl; and

[0125] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33 )(Q 34 )(Q 35 ),and

[0126] Q 33 -Q 35 Each independently selected from:

[0127] -CH 3 、-CD 3 、-CD 2 H.-CDH 2 、-CH 2 CH 3 、-CH 2 CD 3 、-CH 2 CD 2 H, -CH 2 CDH 2 、-CHDCH 3 、-CHDCD 2 H, -CHDCDH 2 、-CHDCD 3 、-CD 2 CD 3 、-CD 2 CD 2 H and -CD 2 CDH 2 ;

[0128] n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl, and naphthyl; and

[0129] each of which is selected from at least one substituted n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl and naphthyl: deuterium, C 1 -C 10 Alkyl and phenyl.

[0130] 9. The organometallic compound according to item 1, wherein in Formula 1A, The moiety represented by is represented by one selected from the formulas CY1-1 to CY1-16:

[0131]

[0132]

[0133] Among them, in formulas CY1-1 to CY1-16,

[0134] Y 1 Same as described in item 1,

[0135] X 11 N or C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 N or C-[(L 12 ) b12 -(R 12 ) c12 ], X 13 N or C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 N or C-[(L 14 ) b14 -(R 14 ) c14 ], X 15 N or C-[(L 15 ) b15 -(R 15 ) c15 ], X 16 N or C-[(L 16 ) b16 -(R 16 ) c16 ], X 17 N or C-[(L 17 ) b17 -(R 17 ) c17 ], X 18 N or C-[(L 18 ) b18 -(R 18 ) c18 ],

[0136] X 19 C(R 19a )(R 19b )、N-[(L 19 ) b19 -(R 19 ) c19 ], O, S, or Si(R 19a )(R 19b ),

[0137] L 11 -L 19 Each independently of the L in item 11 Same as described,

[0138] b11-b19 are each independently the same as described with respect to b1 in item 1,

[0139] R 11 -R 19 and R 19a -R 19c Each independently of the R 1 Same as described,

[0140] c11-c19 are each independently the same as described for c1 in item 1,

[0141] *' represents the binding site to M of Formula 1A, and

[0142] * indicates CY in formula 1A 5 binding site.

[0143] 10. The organometallic compound according to item 1, wherein in Formula 1A, The moiety represented by is represented by one selected from the formulas CY2-1 to CY2-4:

[0144]

[0145] The X in the formula CY2-1 51 O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 ), or C(=O), X in formula CY2-2 to CY2-4 51 N, C (R 7 )、Si(R 7 ), or Ge(R 7 ), L 7 , b7, R 7 , R 8 , c7 and c8 are each independently the same as described in item 1,

[0146] In formulas CY2-1 to CY2-4,

[0147] X 2 Same as described in item 1,

[0148] X 21 N or C-[(L21 ) b21 -(R 21 ) c21 ], X 22 N or C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 N or C-[(L 23 ) b23 -(R 23 ) c23 ],

[0149] L 21 -L 23 Each independently of the L in item 1 2 Same as described,

[0150] b21-b23 are each independently the same as described with respect to b2 in item 1,

[0151] R 21 -R 23 Each independently of the R 2 Same as described,

[0152] c21-c23 are each independently the same as described in item 1 with respect to c2,

[0153] *' represents the binding site to M of Formula 1A,

[0154] * indicates CY in formula 1A 1 The binding site, and

[0155] *" indicates CY of formula 1A 3 binding site.

[0156] 11. The organometallic compound according to item 1, wherein in Formula 1A, The moiety represented by is represented by one selected from the formulas CY3-1 to CY3-11:

[0157]

[0158] Among them, in formulas CY3-1 to CY3-11,

[0159] X 3 Same as described in item 1,

[0160] X 31 N or C-[(L 31 ) b31 -(R 31 ) c31 ], X 32N or C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 N or C-[(L 33 ) b33 -(R 33 ) c33 ], X 34 N or C-[(L 34 ) b34 -(R 34 ) c34 ], X 35 N or C-[(L 35 ) b35 -(R 35 ) c35 ], X 36 N or C-[(L 36 ) b36 -(R 36 ) c36 ], X 37 N or C-[(L 37 ) b37 -(R 37 ) c37 ],

[0161] X 39 C(R 39a )(R 39b )、N-[(L 39 ) b39 -(R 39 ) c39 ], O, S, or Si(R 39a )(R 39b ),

[0162] L 31 -L 37 and L 39 Each independently of the L in item 1 3 Same as described,

[0163] b31-b37 and b39 are each independently the same as described with respect to b3 in item 1,

[0164] R 31 -R 39 and R 39a -R 39b Each independently of the R 3 Same as described,

[0165] c31-c37 and c39 are each independently the same as described in item 1 with respect to c3,

[0166] *' represents the binding site to M of Formula 1A,

[0167] * indicates CY in formula 1A 4 The binding site, and

[0168] *" indicates CY of formula 1A 2 binding site.

[0169] 12. The organometallic compound according to item 1, wherein in Formula 1A, The moiety represented by is represented by one selected from the formulas CY4-1 to CY4-16:

[0170]

[0171]

[0172] Among them, in formulas CY4-1 to CY4-16,

[0173] X 4 Same as described in item 1,

[0174] X 41 N or C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 N or C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 N or C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 N or C-[(L 44 ) b44 -(R 44 ) c44 ], X 45 N or C-[(L 45 ) b45 -(R 45 ) c45 ], X 46 N or C-[(L 46 ) b46 -(R 46 ) c46 ], X 47 N or C-[(L 47 ) b47 -(R 47 ) c47 ], X48 N or C-[(L 48 ) b48 -(R 48 ) c48 ],

[0175] X 49 C(R 49a )(R 49b )、N-[(L 49 ) b49 -(R 49 ) c49 ], O, S, or Si(R 49a )(R 49b ),

[0176] L 41 -L 49 Each independently of the L in item 1 4 Same as described,

[0177] b41-b49 are each independently the same as described with respect to b4 in item 1,

[0178] R 41 -R 49 and R 49a -R 49c Each independently of the R 4 Same as described,

[0179] c41-c49 are each independently the same as described for c4 in item 1,

[0180] *' represents the binding site to M of Formula 1A, and

[0181] * indicates CY in formula 1A 3 binding site.

[0182] 13. The organometallic compound according to item 1, wherein in Formula 1A, The part represented by is represented by one selected from the formulas CY1(1) to CY1(8), The part represented by is represented by one selected from the formulas CY2(1) to CY2(4), represented by The part represented by is represented by one selected from the formulas CY3(1) to CY3(24), and by The portion represented by is represented by one selected from formulas CY4(1) to CY4(67):

[0183]

[0184]

[0185]

[0186]

[0187] Among them, X in formulas CY2(1) to CY2(4) 51 O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 ), or C(=O), and L 7 , b7, R 7 , R 8 , c7 and c8 are each independently the same as described in item 1,

[0188] In formulas CY1(1) to CY1(8), CY2(1) to CY2(4), CY3(1) to CY3(24), and CY4(1) to CY4(67),

[0189] X 2 -X 4 , Y 1 , L 1 -L 4 、b1-b4、R 1 -R 4 and c1-c4 are each independently the same as described in item 1,

[0190] X 39 C(R 39a )(R 39b )、N-[(L 39 ) b39 -(R 39 ) c39 ], O, S, or Si(R 39a )(R 39b ),

[0191] X 49 C(R 49a )(R 49b )、N-[(L 49 ) b49 -(R 49 ) c49 ], O, S, or Si(R 49a )(R 49b ),

[0192] L 1aand L 1b Each independently of the L in item 1 1 Same as described,

[0193] R 1a and R 1b Each independently of the R 1 Same as described,

[0194] L 3a , L 3b and L 39 Each independently of the L in item 1 3 Same as described,

[0195] R 3a , R 3b , R 39 , R 39a and R 39b Each independently of the R 3 Same as described,

[0196] b39 and c39 are each independently the same as described in item 1 with respect to b3 and c3, respectively,

[0197] L 4a , L 4b and L 49 Each independently of the L in item 1 4 Same as described,

[0198] R 4a , R 4b , R 49 , R 49a and R 49b Each independently of the R 4 Same as described,

[0199] b49 and c49 are each independently the same as described in item 1 with respect to b4 and c4, respectively,

[0200] *-(L 1 ) b1 -(R 1 ) c1 、*-(L 1a ) b1 -(R 1a ) c1 、*-(L 1b ) b1 -(R 1b ) c1 、*-(L 2 ) b2 -(R 2 ) c2 、*-(L3 ) b3 -(R 3 ) c3 、*-(L 3a ) b3 -(R 3a ) c3 、*-(L 3b ) b3 -(R 3b ) c3 、*-(L 4 ) b4 -(R 4 ) c4 、*-(L 4a ) b4 -(R 4a ) c4 and *-(L 4b ) b4 -(R 4b ) c4 is not hydrogen, and * indicates a binding site to a neighboring atom,

[0201] In formulae CY1(1) to CY1(8), CY2(1) to CY2(4), CY3(1) to CY3(24), and CY4(1) to CY4(67), *' represents the binding site to M of formula 1A,

[0202] In formulas CY1(1) to CY1(8), * represents CY of formula 1A. 5 The binding site

[0203] In formulas CY2(1) to CY2(4), * represents CY of formula 1A. 1 The binding site of CY of Formula 1A is shown in FIG. 3 The binding site

[0204] In formulas CY3(1) to CY3(24), *" indicates CY of formula 1A. 2 and * indicates the binding site to CY of Formula 1A 4 The binding site, and

[0205] In formulas CY4(1) to CY4(67), * represents CY of formula 1A. 3 binding site.

[0206] 14. The organometallic compound according to item 1, wherein the organometallic compound is represented by Formula 1-1:

[0207]

[0208] Among them, in formula 1-1,

[0209] M, X 1 -X 3 and X 51 Each independently being the same as described in item 1,

[0210] X 11 N or C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 N or C-[(L 12 ) b12 -(R 12 ) c12 ], X 13 N or C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 N or C-[(L 14 ) b14 -(R 14 ) c14 ],

[0211] L 11 -L 14 、b11-b14、R 11 -R 14 and c11-c14 are independently related to L in item 1 1 , b1, R 1 Same as described in c1,

[0212] X 21 N or C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 N or C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 N or C-[(L 23 ) b23 -(R 23 ) c23 ],

[0213] L 21 -L 23 、b21-b23、R 21 -R 23 and c21-c23 are independently related to the L in item 1 2 , b2, R 2Same as described in c2,

[0214] X 31 N or C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 N or C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 N or C-[(L 33 ) b33 -(R 33 ) c33 ],

[0215] L 31 -L 33 、b31-b33、R 31 -R 33 and c31-c33 are independently related to L in item 1 3 , b3, R 3 Same as described in c3,

[0216] X 41 N or C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 N or C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 N or C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 N or C-[(L 44 ) b44 -(R 44 ) c44 ],

[0217] L 41 -L 44 、b41-b44、R 41 -R 44 and c41-c44 are independently related to L in item 1 4 , b4, R 4 Same as described in c4,

[0218] Selected from R 11 -R 14Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0219] Selected from R 21 -R 23 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0220] Selected from R 31 -R 33 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups, and

[0221] Selected from R 41 -R 44 Two of are optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic group.

[0222] 15. The organometallic compound according to item 1, wherein the organometallic compound is one selected from Compounds 1-1 to 1-88, Compounds 2-1 to 2-47, and Compounds 3-1 to 3-582 to be described below.

[0223] 16. Organic light-emitting device, comprising:

[0224] a first electrode;

[0225] a second electrode; and

[0226] an organic layer between the first electrode and the second electrode, the organic layer comprising an emission layer,

[0227] The organic layer comprises at least one of the organometallic compounds described in any one of items 1 to 15.

[0228] 17. The organic light emitting device according to item 16, wherein

[0229] The first electrode is an anode,

[0230] The second electrode is a cathode,

[0231] The organic layer further includes a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode,

[0232] The hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and

[0233] The electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0234] 18. The organic light-emitting device according to item 16, wherein the emission layer comprises the organometallic compound.

[0235] 19. The organic light-emitting device according to item 18, wherein the emission layer further comprises a host, and an amount of the host in the emission layer is greater than an amount of the organometallic compound in the emission layer.

[0236] 20. A diagnostic composition comprising at least one organometallic compound according to any one of items 1 to 15. BRIEF DESCRIPTION OF THE DRAWINGS

[0237] By combining Figure 1 These and / or other aspects will become clear and more readily understood from the following description of the embodiments contemplated herein. Figure 1 is a schematic diagram of an organic light emitting device according to an embodiment. DETAILED DESCRIPTION

[0238] Embodiments will now be described in detail, examples of which are illustrated in the accompanying drawings, wherein the same reference numerals refer to the same elements throughout. In this regard, the present embodiment may have different forms and should not be construed as being limited to the description set forth herein. Therefore, the following description of the embodiments is only by reference to the accompanying drawings to explain aspects of this specification. As used herein, the term "and / or" includes any and all combinations of one or more of the related enumerated items. Expressions such as "at least one (kind) of" when before or after a list of elements modify the entire list of elements without modifying the individual elements of the list.

[0239] The organometallic compound according to an embodiment may be represented by Formula 1A:

[0240] <Formula 1A>

[0241]

[0242] In Formula 1A, M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au).

[0243] For example, M in Formula 1A may be platinum (Pt), but embodiments of the present disclosure are not limited thereto.

[0244] The organometallic compound represented by Formula 1A may be a neutral compound not composed of an ion pair of an anion and a cation.

[0245] In Formula 1A, X 1 Can be O or S, and in X 1 The bond between M and M may be a covalent bond. As used herein, the term "covalent bond" does not include a coordinate bond.

[0246] For example, in Formula 1A, X 1 It may be 0, but the embodiments of the present disclosure are not limited thereto.

[0247] In Formula 1A, X 2 and X 3 can be independently C or N, and X 4 Can be N.

[0248] In one embodiment, in Formula 1A, X 3 Can be C, and X 2 and X 4 Each can be N.

[0249] In Formula 1A, selected from X 2 The key between X 3 and M, and the key between X 4 One of the bonds between and M may be a covalent bond, and the others thereof may each be a coordinate bond.

[0250] In one embodiment, in X 2 and M and the bond between X 4 The bonds between X and M can each be coordination bonds, and 3 The bond between M and M may be a covalent bond.

[0251] For example, in Formula 1A,

[0252] i)X 2 and X 4 Can be N, X respectively 3 Can be C, in X 2 and M and the bond between X 4The bonds between X and M can each be coordination bonds, and 3 The bond between and M may be a covalent bond; or

[0253] ii)X 3 and X 4 Can be N, X respectively 2 Can be C, in X 3 and M and the bond between X 4 The bonds between X and M can each be coordination bonds, and 2 The bond between M and M may be a covalent bond.

[0254] In Formula 1A, Y 1 and Y 3 -Y 5 They may each independently be C or N.

[0255] For example, in Formula 1A, Y 1 and Y 3 Each may be C, but the embodiments of the present disclosure are not limited thereto.

[0256] In Formula 1A, 2 and Y 3 The key between X 2 and Y 4 The key between 4 and Y 5 The key between 5 and X 51 The keys between 51 and Y 3 The bonds between may each be a chemical bond (eg, a single bond, a double bond, a covalent bond, etc.).

[0257] In Formula 1A, CY 1 -CY 5 Can be independently selected from C 5 -C 30 Carbocyclic groups and C 1 -C 30 Here, CY 4 Not a benzimidazole group.

[0258] For example, in Formula 1A, CY 1 -CY 4may be each independently selected from: a) a 6-membered ring, b) a condensed ring having two or more 6-membered rings condensed to each other, and c) a condensed ring having one 5-membered ring and two or more 6-membered rings condensed to each other, wherein the 6-membered ring may be selected from a cyclohexane group, a cyclohexene group, an adamantane group, a norbornane group, a norbornene group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, and a triazine group, and the 5-membered ring may be selected from a cyclopentane group, a cyclopentene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole groups and thiadiazole groups.

[0259] In one embodiment, CY 1 -CY 4 can be independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a benzo[9,10]phenanthrene group, a pyrene group, group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole group, thiadiazole group, benzopyrazole group, benzimidazole group, benzo Azole group, benzothiazole group, benzo oxadiazole group, benzothiadiazole group, 5,6,7,8-tetrahydroisoquinoline group, 5,6,7,8-tetrahydroquinoline group, 5,6,7,8-tetrahydrophthalazine group and 5,6,7,8-tetrahydrocinnoline group.

[0260] In one or more embodiments, CY 1 -CY 4 can be independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a benzo[9,10]phenanthrene group, a pyrene group, Group, cyclopentadiene group, 1,2,3,4-tetrahydronaphthalene group, fluorene group, carbazole group, dibenzofuran group, dibenzothiophene group, dibenzosilole group, azafluorene group, azacarbazole group, azadibenzofuran group, azadibenzothiophene group, azadibenzosilole group, pyridine group, pyrimidine group, pyrazine group, pyridazine group, triazine group, quinoline group, isoquinoline group, quinoxaline group, quinazoline group, phenanthroline group, cinnoline group, phthalazine group, 5,6,7,8-tetrahydroisoquinoline group, 5,6,7,8-tetrahydroquinoline group, 5,6,7,8-tetraphthalazine group, and 5,6,7,8-tetrahydrocinnoline group, but embodiments of the present disclosure are not limited thereto.

[0261] In Formula 1A, CY 5 It may be a 5-membered ring.

[0262] In formula 1A, CY 5 CY 2 CY 3 The cyclometallated ring formed with M may be a 6-membered ring.

[0263] In Formula 1A, X 51 Can be selected from O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 )、C(=O)、N、C(R 7 )、Si(R 7 ) and Ge(R 7 ), R 7 and R 8 Can be optionally linked via a first linking group to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups (e.g., C 5 -C 6 5- to 7-membered cyclic groups; or deuterated, cyano, -F, C 1 -C 10 Alkyl and C 6 -C 14 At least one substituted C 5 -C 6 5- to 7-membered cyclic group). Here, L 7 , b7, R 7, c7 and R 8 Each is independently the same as described below.

[0264] The first linking group may be selected from a single bond, *-O-*', *-S-*', *-C(R 5 )(R 6 )-*'、*-C(R 5 )=*'、*=C(R 6 )-*'、*-C(R 5 )=C(R 6 )-*', *-C(=O)-*', *-C(=S)-*', *-C≡C-*', *-N(R 5 )-*'、*-Si(R 5 )(R 6 )-*' and *-P(R 5 )(R 6 )-*',R 5 and R 6 Each independently and with respect to R 1 The descriptions are the same, and * and *' each represent a binding site to an adjacent atom.

[0265] In Formula 1A, L 1 -L 4 and L 7 may be independently selected from substituted or unsubstituted C 5 -C 30 Carbocyclic groups and substituted or unsubstituted C 1 -C 30 Heterocyclic group.

[0266] For example, in Formula 1A, L 1 -L 4 and L 7 Can be independently selected from:

[0267] Benzene group, naphthalene group, anthracene group, phenanthrene group, benzo[9,10]phenanthrene group, pyrene group, group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzothioole group, a dibenzothioole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzothioole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole group, thiadiazole group, benzopyrazole group, benzimidazole group, benzo Azole group, benzothiazole group, benzo oxadiazole groups and benzothiadiazole groups; and

[0268] Each of which is selected from at least one substituted phenyl group, naphthalene group, anthracene group, phenanthrene group, benzo[9,10]phenanthrene group, pyrene group, group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzothioole group, a dibenzothioole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzothioole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole group, thiadiazole group, benzopyrazole group, benzimidazole group, benzo Azole group, benzothiazole group, benzo oxadiazole group and benzothiadiazole group: deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, phenyl, naphthyl, pyridyl, pyrimidyl, triazine, fluorenyl, dimethylfluorenyl, diphenylfluorenyl, carbazolyl, phenylcarbazolyl, dibenzofuranyl, dibenzothiophenyl, dibenzosilyl, dimethyldibenzosilyl, diphenyldibenzosilyl, -N(Q 31 )(Q 32 )、-Si(Q 33 )(Q 34 )(Q 35 )、-B(Q 36 )(Q 37 ) and -P(=O)(Q 38 )(Q 39 ),

[0269] Q 31 -Q 39 Can be independently selected from:

[0270] -CH 3 、-CD3 、-CD 2 H.-CDH 2 、-CH 2 CH 3 、-CH 2 CD 3 、-CH 2 CD 2 H, -CH 2 CDH 2 、-CHDCH 3 、-CHDCD 2 H, -CHDCDH 2 、-CHDCD 3 、-CD 2 CD 3 、-CD 2 CD 2 H and -CD 2 CDH 2 ;

[0271] n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl, and naphthyl; and

[0272] each of which is selected from at least one substituted n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, phenyl and naphthyl: deuterium, C 1 -C 10 Alkyl and phenyl,

[0273] However, the implementation of the present disclosure is not limited thereto.

[0274] In one embodiment, in Formula 1A, L 1 -L 4 and L 7 Can be independently selected from:

[0275] phenyl groups, pyridine groups and pyrimidine groups; and

[0276] A phenyl group, a pyridine group and a pyrimidine group, each of which is selected from at least one substituted group consisting of deuterium, -F, -Cl, -Br, -I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidine group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, phenyl, pyridyl and pyrimidinyl, -N(Q 31 )(Q 32 )、-Si(Q 33 )(Q 34 )(Q35 )、-B(Q 36 )(Q 37 ) and -P(=O)(Q 38 )(Q 39 )(where Q 31 -Q 39 each independently the same as described herein),

[0277] However, the implementation of the present disclosure is not limited thereto.

[0278] In Formula 1A, b1-b4 and b7 represent L 1 -L 4 and L 7 The number of, and each independently can be an integer of 0-5. When b1 is 0, *-(L 1 ) b1 -*' may be a single bond. When b1 is 2 or greater, two or more L 1 b2-b4 and b7 are each independently the same as described with respect to b1.

[0279] In one embodiment, in Formula 1A, b1-b4 and b7 may each independently be 0 or 1, but embodiments of the present disclosure are not limited thereto.

[0280] In Formula 1A, R 1 -R 4 , R 7 and R 8 can be independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, -SF 5 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, substituted or unsubstituted C 1 -C 60 Alkyl, substituted or unsubstituted C 2 -C 60 Alkenyl, substituted or unsubstituted C 2 -C 60 Alkynyl, substituted or unsubstituted C 1 -C 60 Alkoxy, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60Aryl, substituted or unsubstituted C 6 -C 60 Aryloxy, substituted or unsubstituted C 6 -C 60 Arylthio, substituted or unsubstituted C 1 -C 60 heteroaryl, a substituted or unsubstituted monovalent non-aromatic fused polycyclic group, a substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ).

[0281] For example, R 1 -R 4 , R 7 and R 8 Can be independently selected from:

[0282] hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, -SF 5 , C 1 -C 20 Alkyl and C 1 -C 20 Alkoxy;

[0283] Each of the following is substituted by at least one C 1 -C 20 Alkyl and C 1 -C 20 Alkoxy: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl;

[0284] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl;

[0285] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33 )(Q 34 )(Q 35 );and

[0286] -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 ),and

[0287] Q 1 -Q 9 and Q 33 -Q 35 Each independently and with respect to Q 31 Same as described.

[0288] In one embodiment, R 1 -R 4 , R 7 and R 8 Can be independently selected from:

[0289] Hydrogen, deuterium, -F, cyano, nitro, -SF 5, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, n-heptyl, isoheptyl, sec-heptyl, tert-heptyl, n-octyl, isooctyl, sec-octyl, tert-octyl, n-nonyl, isononyl, sec-nonyl, tert-nonyl, n-decyl, isodecyl, sec-decyl, tert-decyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, fluorenyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl and dibenzosilyl;

[0290] substituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, n-heptyl, isoheptyl, sec-heptyl, tert-heptyl, n-octyl, isooctyl, sec-octyl, tert-octyl, n-nonyl, isononyl, sec-nonyl, tert-nonyl, n-decyl, isodecyl, sec-decyl, tert-decyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, fluorenyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl and dibenzosilyl, each of which is selected from at least one substituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, tert-pentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, n-heptyl, isoheptyl, sec-heptyl, tert-heptyl, n-octyl, isooctyl, sec-octyl, tert-octyl, n-nonyl, isononyl, sec-nonyl, tert-nonyl, n-decyl, isodecyl, sec-decyl, tert-decyl, methoxy, ethoxy, propoxy, butoxy, 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , cyano, nitro, C 1 -C 10 Alkyl, C 1 -C 10 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, fluorenyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, dibenzosilyl and -Si(Q) 33 )(Q 34 )(Q 35 );and

[0291] -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q8 )(Q 9 ),and

[0292] Q 1 -Q 9 and Q 33 -Q 35 Each is independently the same as described herein, but embodiments of the present disclosure are not limited thereto.

[0293] In one or more embodiments, R 1 -R 4 , R 7 and R 8 can be independently selected from hydrogen, deuterium, -F, cyano, nitro, -SF 5 、-CH 3 、-CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , -C 2 F 5 , -C 2 F 4 H, -C 2 F 3 H 2 , -C 2 F 2 H 3 , -C 2 FH 4 , groups represented by formulae 9-1 to 9-19, groups represented by formulae 10-1 to 10-167, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 )(where Q 1 -Q 9 Each independently the same as described herein), but the embodiments of the present disclosure are not limited thereto:

[0294]

[0295]

[0296]

[0297]

[0298] In the groups represented by Formulae 9-1 to 9-19 and Formulae 10-1 to 10-167, * represents a bonding site with an adjacent group, Ph represents a phenyl group, and TMS represents a trimethylsilyl group.

[0299] In Formula 1A, c1-c4 represent R 1 -R 4 When c1 is 2 or more, two or more R 1 c2-c4 are each independently the same as described for c1.

[0300] In one embodiment, in Formula 1A, c1-c4 may each independently be 1 or 2, but embodiments of the present disclosure are not limited thereto.

[0301] In Formula 1A, a1-a4 represent *-[(L 1 ) b1 -(R 1 ) c1 ]、*-[(L 2 ) b2 -(R 2 ) c2 ]、*-[(L 3 ) b3 -(R 3 ) c3 ] and *-[(L 4 ) b4 -(R 4 ) c4 ], and each independently can be 0, 1, 2, 3, 4 or 5. When a1 is 2 or greater, two or more *-[(L 1 ) b1 -(R 1 ) c1 ] may be the same or different from each other. When a2 is 2 or greater, two or more *-[(L 2 ) b2 -(R 2 ) c2 ] may be the same or different from each other. When a3 is 2 or greater, two or more *-[(L 3 ) b3 -(R 3 ) c3 ] may be the same or different from each other. When a4 is 2 or greater, two or more *-[(L 4 ) b4 -(R 4 ) c4] may be the same as or different from each other. However, the embodiments of the present disclosure are not limited thereto.

[0302] For example, in Formula 1A, a1-a4 can each independently be 1, 2, 3, 4 or 5, and

[0303] i) selected from R 1 -R 4 At least one of may not be hydrogen,

[0304] ii) selected from R 1 , R 2 and R 4 At least one of may not be hydrogen,

[0305] iii) selected from R 1 -R 3 At least one of may not be hydrogen, or

[0306] iv) selected from R 1 and R 2 At least one of may not be hydrogen, but embodiments of the present disclosure are not limited thereto.

[0307] In Formula 1A, i) multiple adjacent R 1 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, ii) multiple adjacent R 2 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iii) multiple adjacent R 3 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iv) multiple adjacent R 4 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, and v) is selected from R 1 -R 4 Two or more adjacent groups of may be optionally linked to form a substituted or unsubstituted C 5 -C 30A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic group.

[0308] For example, in Formula 1A, i) by placing multiple adjacent R 1 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, ii) by placing multiple adjacent R 2 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iii) by placing multiple adjacent R 3 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iv) by placing multiple adjacent R 4 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, and v) by selecting R 1 -R 4 Two or more adjacent groups are connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 The heterocyclic groups may each independently be selected from:

[0309] a pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a norbornane group, a norbornene group, a bicycloheptane group, a bicyclooctane group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group; and

[0310] Each is at least one R 1aa substituted pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a norbornane group, a norbornene group, a bicycloheptane group, a bicyclooctane group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group,

[0311] However, the implementation of the present disclosure is not limited thereto.

[0312] R 1a Can be related to R 1 Same as described.

[0313] As used herein, the “azabenzothiophene group, azabenzofuran group, azaindene group, azaindole group, azabenzosilole group, azadibenzothiophene group, azadibenzofuran group, azafluorene group, azacarbazole group and azadibenzosilole group” mean a heterocyclic ring having the same skeleton as the “benzothiophene group, benzofuran group, indene group, indole group, benzosilole group, dibenzothiophene group, dibenzofuran group, fluorene group, carbazole group and dibenzosilole group”, respectively, in which at least one of the carbons forming the ring thereof is replaced by nitrogen.

[0314] In one embodiment, in Formula 1A,

[0315] i) In Y 3 and X 51 The key between 5 and X 51 The bonds between can each be single bonds, and X 51 Can be C(R 7 )(R 8 )、Si(R 7 )(R 8 ), or C(=O),

[0316] ii) In Y 3 and X 51 The key between 5 and X 51 The bonds between X and X can each be a single bond. 51 Can be N-[(L 7 ) b7 -(R 7 ) c7 ], and R 7 Can be selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 6 -C 60 Aryloxy, substituted or unsubstituted C 6 -C 60 Arylthio, substituted or unsubstituted C 1 -C 60 heteroaryl, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, or

[0317] iii) selected from Y 3 and X 51 The key between 5 and X 51 One of the bonds between may be a single bond, and the other may each be a double bond, and X 51 Can be N, C (R 7 ), or Si(R 7 ).

[0318] In one or more embodiments, in Formula 1A, X 51 Can be N-[(L 7 ) b7 -(R 7 ) c7 ], and R 7 You can choose from:

[0319] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazineyl, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, and imidazopyrimidinyl; and

[0320] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazole, triazine, dibenzofuranyl, dibenzothiophenyl, benzocarbazolyl, dibenzothioyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q 33 )(Q 34 )(Q 35 ),and

[0321] Q 33 -Q 35 Each is independently the same as described herein.

[0322] In one or more embodiments, in Formula 1A, X 51 Can be N-[(L 7 ) b7 -(R 7 ) c7 ], and R 7 The groups represented by Formulae 10-1 to 10-128 and the groups represented by Formulae 10-131 to 10-167 may be selected, but the embodiments of the present disclosure are not limited thereto.

[0323] In one or more embodiments, in Formula 1A,

[0324] Where i) M is Pt, ii) X 1 O, iii)X 2 and X 4 Each is N, X 3 For C, in X 2 and M and the bond between X 4 The bonds between X and M are each coordination bonds, and 3 The bond between Y and M is a covalent bond, iv) 1 and Y 3 -Y 5 Each is C, v) in Y 5 and X 51 The key between 3 and X 51 The bonds between are each single bonds, vi)CY 1 CY 2 and CY 3 Each is a phenyl group, and CY 4 is a pyridine group, vii) X 51 O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ], and viii) b7 is 0, c7 is 1, and R 7 is substituted or unsubstituted C 1 -C 60 In the case of alkyl,

[0325] a1-a4 can be 1, 2, 3, 4 or 5 independently of each other and are selected from R 1 -R 4 At least one of which may be selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 1 -C 60 a heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.

[0326] In one or more embodiments, wherein X 51 Can be O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ], b7 can be 0, c7 can be 1, and R 7 Can be substituted or unsubstituted C 1 -C 60 The alkyl group of Formula 1A may satisfy at least one selected from <Condition 1> to <Condition 6>:

[0327] <Condition 1>

[0328] M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), or gold (Au);

[0329] <Condition 2>

[0330] X 1 Can be S;

[0331] <Condition 3>

[0332] X 3 and X 4 Can be N, X respectively 2 Can be C, in X 3 and M and the bond between X 4 The bonds between X and M can each be coordination bonds, and2 The bond between and M may be a covalent bond;

[0333] <Condition 4>

[0334] Selected from Y 1 and Y 3 -Y 5 At least one of may not be C;

[0335] <Condition 5>

[0336] Selected from CY 1 CY 2 and CY 3 At least one of may not be a phenyl group; and

[0337] <Condition 6>

[0338] CY 4 It may not be a pyridine group.

[0339] In one or more embodiments, the organometallic compound may be represented by Formula 1A, wherein

[0340] M can be Pt,

[0341] X 1 Can be O,

[0342] X 2 and X 4 Can be N, X respectively 3 Can be C, in X 2 and M and the bond between X 4 The bonds between X and M can each be coordination bonds. 3 The bond between and M may be a covalent bond,

[0343] Y 1 and Y 3 -Y 5 Can be C,

[0344] In Y 5 and X 51 The key between 3 and X 51 The bonds between can each be single bonds,

[0345] CY 1 CY 2 and CY 3 Each of them can be a phenyl group, CY 4 may be a pyridine group,

[0346] X 51 Can be O, S, or N-[(L 7 ) b7 -(R 7) c7 ],

[0347] b7 can be 0, c7 can be 1, R 7 Can be substituted or unsubstituted C 1 -C 60 alkyl,

[0348] a1-a4 can each independently be 1, 2, 3 or 4, and

[0349] Selected from R 1 -R 4 At least one of which may be independently selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 1 -C 60 a heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group.

[0350] In one or more embodiments, the organometallic compound may be represented by Formula 1A, wherein

[0351] M can be Pt,

[0352] X 1 Can be O,

[0353] X 2 and X 4 Can be N, X respectively 3 Can be C, in X 2 and M and the bond between X 4 The bonds between X and M can each be coordination bonds. 3 The bond between and M may be a covalent bond,

[0354] Y 1 and Y 3 -Y 5 Can be C,

[0355] In Y 5 and X 51 The key between 3 and X 51 The bonds between can each be single bonds,

[0356] CY 1 CY 2 and CY 3 Each of them can be a phenyl group, CY 4 may be a pyridine group,

[0357] X 51 Can be O, S, N-[(L 7 ) b7 -(R 7 ) c7 ],

[0358] b7 can be 0, c7 can be 1,

[0359] R 7 You can choose from:

[0360] C 1 -C 30 Alkyl; and

[0361] C substituted by at least one selected from the following 1 -C 30 Alkyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, C 1 -C 10 alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl,

[0362] a1-a4 can each independently be 1, 2, 3 or 4, and

[0363] Selected from R 1 -R 4 At least one of can be independently selected from:

[0364] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazineyl, dibenzofuranyl, dibenzothiophenyl, benzocarbazolyl, dibenzothioyl, dibenzocarbazolyl, imidazopyridinyl, and imidazopyrimidinyl; and

[0365] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33 )(Q 34 )(Q 35 )(where Q 33 -Q 35 each independently the same as described herein),

[0366] However, the implementation of the present disclosure is not limited thereto.

[0367] In one or more embodiments, in Formula 1A,

[0368] X 51 Can be O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ], b7 can be 0, c7 can be 1,

[0369] R 7 You can choose from:

[0370] C 1 -C 30 Alkyl; and

[0371] C substituted by at least one selected from the following 1 -C 30 Alkyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, C 1 -C 10 alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl,

[0372] a1-a4 can each independently be 1, 2, 3, or 4, and

[0373] Selected from R 1 -R 4 At least one of can be independently selected from:

[0374] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazineyl, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, and imidazopyrimidinyl; and

[0375] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33 )(Q 34 )(Q 35 )(where Q 33 -Q 35 each independently the same as described herein).

[0376] In one embodiment, in Formula 1A, The moiety represented by may be represented by one selected from the formulas CY1-1 to CY1-16:

[0377]

[0378] In formulas CY1-1 to CY1-16,

[0379] Y 1 can be the same as described in this article,

[0380] X 11 Can be N or C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 Can be N or C-[(L 12 ) b12 -(R12 ) c12 ], X 13 Can be N or C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 Can be N or C-[(L 14 ) b14 -(R 14 ) c14 ], X 15 Can be N or C-[(L 15 ) b15 -(R 15 ) c15 ], X 16 Can be N or C-[(L 16 ) b16 -(R 16 ) c16 ], X 17 Can be N or C-[(L 17 ) b17 -(R 17 ) c17 ], X 18 Can be N or C-[(L 18 ) b18 -(R 18 ) c18 ],

[0381] X 19 Can be C(R 19a )(R 19b )、N-[(L 19 ) b19 -(R 19 ) c19 ], O, S, or Si(R 19a )(R 19b ),

[0382] L 11 -L 19 Can be independently related to L 1 Same as described,

[0383] b11-b19 can each independently be the same as described with respect to b1,

[0384] R 11 -R 19 and R 19a -R 19c Can be independently related to R 1 Same as described,

[0385] c11-c19 can each independently be the same as described for c1,

[0386] *' represents the binding site to M of Formula 1A, and

[0387] * indicates CY in formula 1A 5 binding site.

[0388] In one or more embodiments, in Formula 1A, The part represented by can be represented by one selected from formulas A1(1) to A1(30):

[0389]

[0390]

[0391]

[0392] In formulas A1(1) to A1(30),

[0393] Y 1 , L 1 , b1, R 1 and c1 may each independently be the same as described herein,

[0394] X 19 Can be C(R 19a )(R 19b )、N-[(L 19 ) b19 -(R 19 ) c19 ], O, S, or Si(R 19a )(R 19b ),

[0395] L 19 , b19 and c19 can each independently be related to L 1 , b1 and c1 describe the same thing,

[0396] R 15 -R 19 and R 19a -R 19c Can be independently related to R 1 Same as described,

[0397] a16 can be an integer from 0 to 6.

[0398] a15 can be an integer from 0 to 5.

[0399] a14 can be an integer from 0 to 4.

[0400] a13 can be an integer from 0 to 3.

[0401] a12 can be an integer from 0 to 2.

[0402] *' represents the binding site to M of Formula 1A, and

[0403] * indicates CY in formula 1A 5 binding site.

[0404] In one or more embodiments, in Formula 1A, The moiety represented by may be represented by one selected from the formulas CY2-1 to CY2-4:

[0405]

[0406] X in formula CY2-1 51 Can be O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 ), or C(=O), X in formula CY2-2 to CY2-4 51 Can be N, C (R 7 )、Si(R 7 ), or Ge(R 7 ), L 7 , b7, R 7 , R 8 , c7 and c8 may each independently be the same as described herein,

[0407] In formulas CY2-1 to CY2-4,

[0408] X 2 can be the same as described in this article,

[0409] X 21 Can be N or C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 Can be N or C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 Can be N or C-[(L 23 ) b23 -(R 23 ) c23 ],

[0410] L21 -L 23 Can be independently related to L 2 Same as described,

[0411] b21-b23 may each independently be the same as described with respect to b2,

[0412] R 21 -R 23 Can be independently related to R 2 Same as described,

[0413] c21-c23 can each independently be the same as described for c2,

[0414] *' represents the binding site to M of Formula 1A,

[0415] * indicates CY in formula 1A 1 The binding site, and

[0416] *" indicates CY of formula 1A 3 binding site.

[0417] In one or more embodiments, in Formula 1A, The part represented by can be represented by one selected from formulas A2(1) to A2(16):

[0418]

[0419]

[0420] X in formulas A2(1) to A2(4) 51 Can be O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 ), or C(═O), X in formulas A2(5) to A2(16) 51 Can be N, C (R 7 )、Si(R 7 ), or Ge(R 7 ), L 7 , b7, R 7 , R 8 , c7 and c8 may each independently be the same as described herein,

[0421] In formulas A2(1) to A2(16),

[0422] X 2 , L 2 , b2, R 2 and c2 may each independently be the same as described herein,

[0423] a23 can be an integer from 0 to 3.

[0424] a22 can be an integer from 0 to 2.

[0425] *' represents the binding site to M of Formula 1A,

[0426] * indicates CY in formula 1A 1 The binding site, and

[0427] *" indicates CY of formula 1A 3 binding site.

[0428] In one or more embodiments, in Formula 1A, The moiety represented by may be represented by one selected from the formulas CY3-1 to CY3-11:

[0429]

[0430] In formulas CY3-1 to CY3-11,

[0431] X 3 can be the same as described in this article,

[0432] X 31 Can be N or C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 Can be N or C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 Can be N or C-[(L 33 ) b33 -(R 33 ) c33 ], X 34 Can be N or C-[(L 34 ) b34 -(R 34 ) c34 ], X 35 Can be N or C-[(L 35 ) b35 -(R 35 ) c35 ], X 36 Can be N or C-[(L36 ) b36 -(R 36 ) c36 ], X 37 Can be N or C-[(L 37 ) b37 -(R 37 ) c37 ],

[0433] X 39 Can be C(R 39a )(R 39b )、N-[(L 39 ) b39 -(R 39 ) c39 ], O, S, or Si(R 39a )(R 39b ),

[0434] L 31 -L 37 and L 39 Can be independently related to L 3 Same as described,

[0435] b31-b37 and b39 may each independently be the same as described with respect to b3,

[0436] R 31 -R 39 and R 39a -R 39b Can be independently related to R 3 Same as described,

[0437] c31-c37 and c39 can each independently be the same as described for c3,

[0438] *' represents the binding site to M of Formula 1A,

[0439] * indicates CY in formula 1A 4 The binding site, and

[0440] *" indicates CY of formula 1A 2 binding site.

[0441] In one or more embodiments, in Formula 1A, The part represented by can be represented by one selected from formulas A3(1) to A3(17):

[0442]

[0443] In formulas A3(1) to A3(17),

[0444] X 3, L 3 , b3, R 3 and c3 may each independently be the same as described herein,

[0445] X 39 Can be C(R 39a )(R 39b )、N-[(L 39 ) b39 -(R 39 ) c39 ], O, S, or Si(R 39a )(R 39b ),

[0446] L 39 , b39 and c39 can each independently be related to L 3 , b3 and c3 describe the same,

[0447] R 31 -R 39 and R 39a -R 39b Can be independently related to R 3 Same as described,

[0448] a35 can be an integer from 0 to 5.

[0449] a34 can be an integer from 0 to 4.

[0450] a33 can be an integer from 0 to 3.

[0451] a32 can be an integer from 0 to 2.

[0452] *' represents the binding site to M of Formula 1A,

[0453] * indicates CY in formula 1A 4 The binding site, and

[0454] *" indicates CY of formula 1A 2 binding site.

[0455] In one or more embodiments, in Formula 1A, The moiety represented by may be represented by one selected from the formulas CY4-1 to CY4-16:

[0456]

[0457]

[0458] In formulas CY4-1 to CY4-16,

[0459] X 4 can be the same as described in this article,

[0460] X 41 Can be N or C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 Can be N or C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 Can be N or C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 Can be N or C-[(L 44 ) b44 -(R 44 ) c44 ], X 45 Can be N or C-[(L 45 ) b45 -(R 45 ) c45 ], X 46 Can be N or C-[(L 46 ) b46 -(R 46 ) c46 ], X 47 Can be N or C-[(L 47 ) b47 -(R 47 ) c47 ], X 48 Can be N or C-[(L 48 ) b48 -(R 48 ) c48 ],

[0461] X 49 Can be C(R 49a )(R 49b )、N-[(L 49 ) b49 -(R 49 ) c49 ], O, S, or Si(R 49a )(R 49b ),

[0462] L 41 -L 49 Can be independently related to L 4 Same as described,

[0463] b41-b49 may each independently be the same as described with respect to b4,

[0464] R 41 -R 49 and R 49a -R 49c Can be independently related to R 4 Same as described,

[0465] c41-c49 can each independently be the same as described for c4,

[0466] *' represents the binding site to M of Formula 1A, and

[0467] * indicates CY in formula 1A 3 binding site.

[0468] In one or more embodiments, in Formula 1A, The part represented by can be represented by one selected from formulas A4(1) to A4(45):

[0469]

[0470]

[0471]

[0472]

[0473] In formulas A4(1) to A4(45),

[0474] X 4 , L 4 , b4, R 4 and c4 may each independently be the same as described herein,

[0475] X 49 Can be C(R 49a )(R 49b )、N-[(L 49 ) b49 -(R 49 ) c49 ], O, S, or Si(R 49a )(R 49b ),

[0476] L 49 , b49 and c49 can each independently be related to L 4 , b4 and c4 describe the same,

[0477] R 45 -R 49 and R 49a -R 49c Can be independently related to R4 Same as described,

[0478] a46 can be an integer from 0 to 6.

[0479] a45 can be an integer from 0 to 5.

[0480] a44 can be an integer from 0 to 4.

[0481] a43 can be an integer from 0 to 3.

[0482] a42 can be an integer from 0 to 2.

[0483] *' represents the binding site to M of Formula 1A, and

[0484] * indicates CY in formula 1A 3 binding site.

[0485] In one or more embodiments, in Formula 1A, The moiety represented by may be represented by one selected from the formulas CY1(1) to CY1(8), and / or by The moiety represented by may be represented by one selected from the formulas CY2(1) to CY2(4), and / or by The moiety represented by may be represented by one selected from the formulas CY3(1) to CY3(24), and / or by The part represented by can be represented by one selected from formulas CY4(1) to CY4(67):

[0486]

[0487]

[0488]

[0489]

[0490] X in formulas CY2(1) to CY2(4) 51 Can be O, S, N-[(L 7 ) b7 -(R 7 ) c7 ]、C(R 7 )(R 8 )、Si(R 7 )(R 8 )、Ge(R 7 )(R 8 ), or C(=O), L 7 , b7, R 7 , R 8 , c7 and c8 may each independently be the same as described herein,

[0491] In formulae CY1(1) to CY1(8), formulae CY2(1) to CY2(4), formulae CY3(1) to CY3(24), and formulae CY4(1) to CY4(67),

[0492] X 2 -X 4 , Y 1 , L 1 -L 4 、b1-b4、R 1 -R 4 and c1-c4 may each independently be the same as described herein,

[0493] X 39 Can be C(R 39a )(R 39b )、N-[(L 39 ) b39 -(R 39 ) c39 ], O, S, or Si(R 39a )(R 39b ),

[0494] X 49 Can be C(R 49a )(R 49b )、N-[(L 49 ) b49 -(R 49 ) c49 ], O, S, or Si(R 49a )(R 49b ),

[0495] L 1a and L 1b Can be independently related to L 1 Same as described,

[0496] R 1a and R 1b Can be independently related to R 1 Same as described,

[0497] L 3a , L 3b and L 39 Can be independently related to L 3 Same as described,

[0498] R 3a , R 3b , R 39 , R 39a and R 39b Can be independently related to R 3Same as described,

[0499] b39 and c39 may each independently be the same as described with respect to b3 and c3,

[0500] L 4a , L 4b and L 49 Can be independently related to L 4 Same as described,

[0501] R 4a , R 4b , R 49 , R 49a and R 49b Can be independently related to R 4 Same as described,

[0502] b49 and c49 may each independently be the same as described with respect to b4 and c4,

[0503] *-(L 1 ) b1 -(R 1 ) c1 、*-(L 1a ) b1 -(R 1a ) c1 、*-(L 1b ) b1 -(R 1b ) c1 、*-(L 2 ) b2 -(R 2 ) c2 、*-(L 3 ) b3 -(R 3 ) c3 、*-(L 3a ) b3 -(R 3a ) c3 、*-(L 3b ) b3 -(R 3b ) c3 、*-(L 4 ) b4 -(R 4 ) c4 、*-(L 4a ) b4 -(R 4a ) c4 and *-(L 4b ) b4 -(R 4b ) c4may each be other than hydrogen, wherein * indicates a bonding site to a neighboring atom,

[0504] In formulae CY1(1) to CY1(8), CY2(1) to CY2(4), CY3(1) to CY3(24), and CY4(1) to CY4(67), *' represents the binding site to M of formula 1A,

[0505] In formulas CY1(1) to CY1(8), * represents CY of formula 1A. 5 The binding site

[0506] In formulas CY2(1) to CY2(4), * represents CY of formula 1A. 1 The binding site of CY of Formula 1A is represented by * 3 The binding site

[0507] In formulas CY3(1) to CY3(24), *" indicates CY of formula 1A. 2 and * indicates the binding site to CY of Formula 1A 4 The binding site, and

[0508] In formulas CY4(1) to CY4(67), * represents CY of formula 1A. 3 binding site.

[0509] In one or more embodiments, the organometallic compound may be represented by Formula 1:

[0510] <Formula 1>

[0511]

[0512] In formula 1,

[0513] M, X 1 -X 4 , Y 1 , Y 3 -Y 5 CY 1 -CY 5 , X 51 (where X in Formula 1 51 Not N, C(R 7 )、Si(R 7 ), or Ge(R 7 ))、L 1 -L 4 , L 7 , b1-b4, b7, R 1 -R 4 , c1-c4 and a1-a4 may each independently be the same as described herein,

[0514] Y 2 , Y 6 -Y 9 can be independently N or C,

[0515] Y 10 and Y 11 may each independently be C, N, O or S, and

[0516] In Y 1 and Y 10 The key between 1 and Y 2 The key between X 2 and Y 3 The key between X 2 and Y 4 The key between 4 and Y 5 The key between 4 and Y 6 The key between X 3 and Y 7 The key between X 3 and Y 8 The key between X 4 and Y 9 The key between, and in X 4 and Y 11 The bonds between Y and Y can be independently single or double bonds. 2 and Y 3 The key between 6 and Y 7 The keys between 8 and Y 9 The bonds between may each be a single bond.

[0517] In one or more embodiments, the organometallic compound may be represented by Formula 1-1:

[0518]

[0519] In formula 1-1,

[0520] M, X 1 -X 3 and X 51 may each independently be the same as described herein,

[0521] X 11 Can be N or C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 Can be N or C-[(L 12 )b12 -(R 12 ) c12 ], X 13 Can be N or C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 Can be N or C-[(L 14 ) b14 -(R 14 ) c14 ],

[0522] L 11 -L 14 、b11-b14、R 11 -R 14 and c11-c14 can each be independently related to L 1 , b1, R 1 Same as described in c1,

[0523] X 21 Can be N or C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 Can be N or C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 Can be N or C-[(L 23 ) b23 -(R 23 ) c23 ],

[0524] L 21 -L 23 、b21-b23、R 21 -R 23 and c21-c23 can each independently be related to L 2 , b2, R 2 Same as described in c2,

[0525] X 31 Can be N or C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 Can be N or C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 Can be N or C-[(L33 ) b33 -(R 33 ) c33 ],

[0526] L 31 -L 33 、b31-b33、R 31 -R 33 and c31-c33 can each independently be related to L 3 , b3, R 3 Same as described in c3,

[0527] X 41 Can be N or C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 Can be N or C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 Can be N or C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 Can be N or C-[(L 44 ) b44 -(R 44 ) c44 ],

[0528] L 41 -L 44 、b41-b44、R 41 -R 44 and c41-c44 can each independently be related to L 4 , b4, R 4 Same as described in c4,

[0529] R 11 -R 14 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups,

[0530] R 21 -R 23 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C30 Heterocyclic groups,

[0531] R 31 -R 33 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic groups, and

[0532] R 41 -R 44 Two of may be optionally linked to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 Heterocyclic group.

[0533] For example, in Formula 1-1, i) by 11 -R 14 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, ii) by R 21 -R 23 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iii) by R 31 -R 32 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, iv) by R 41 -R 44 Two connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, and v) by selecting R 11 -R 14 , R 21 -R 23 , R 31 -R 33 and R 41 -R 44Two or more adjacent groups are connected to form a substituted or unsubstituted C 5 -C 30 A carbocyclic group or a substituted or unsubstituted C 1 -C 30 The heterocyclic groups may each independently be selected from:

[0534] a pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a norbornane group, a norbornene group, a bicycloheptane group, a bicyclooctane group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group; and

[0535] Each is at least one R 1a a substituted pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a norbornane group, a norbornene group, a bicycloheptane group, a bicyclooctane group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group,

[0536] However, the implementation of the present disclosure is not limited thereto.

[0537] R 1a Can be related to R 1 Same as described.

[0538] For example, the organometallic compound may be represented by Formula 1-1, and in Formula 1-1,

[0539] X 11 Can be C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 Can be C-[(L 12 ) b12 -(R 12 ) c12 ], X 13 Can be C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 Can be C-[(L14 ) b14 -(R 14 ) c14 ], X 21 Can be C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 Can be C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 Can be C-[(L 23 ) b23 -(R 23 ) c23 ], X 31 Can be C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 Can be C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 Can be C-[(L 33 ) b33 -(R 33 ) c33 ], X 41 Can be C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 Can be C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 Can be C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 Can be C-[(L 44 ) b44 -(R 44 ) c44 ],

[0540] X 51 Can be O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ],

[0541] b7 can be 0, c7 can be 1,

[0542] R 7 You can choose from:

[0543] C 1 -C 30 Alkyl; and

[0544] C substituted by at least one selected from the following 1 -C 30 Alkyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, C 1 -C 10 alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl, and

[0545] Selected from R 11 -R 14 , R 21 -R 23 , R 31 -R 33 and R 41 -R 44 At least one of:

[0546] Cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazineyl, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, and imidazopyrimidinyl; and

[0547] Each of which is selected from at least one substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, Oxazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl and imidazopyrimidinyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, fluorenyl, phenanthrenyl, anthracenyl, fluoranthenyl, benzo[9,10]phenanthrenyl, pyrenyl, yl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, Azolyl, iso oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, benzoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, phenanthrolinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, isobenzothiazolyl, benzo Azolyl, isobenzo Azolyl, triazolyl, tetrazolyl, oxadiazolyl, triazine, dibenzofuranyl, dibenzothiophenyl, dibenzothioyl, benzocarbazolyl, dibenzocarbazolyl, imidazopyridinyl, imidazopyrimidinyl and -Si(Q) 33 )(Q 34 )(Q 35 )(where Q 33 -Q 35 each independently the same as described herein),

[0548] However, the implementation of the present disclosure is not limited thereto.

[0549] In one or more embodiments, the organometallic compound may be represented by Formula 1-1, and in Formula 1-1,

[0550] X 11 Can be C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 Can be C-[(L 12 ) b12 -(R 12 ) c12 ], X 13 Can be C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 Can be C-[(L 14 ) b14 -(R 14 ) c14 ], X 21 Can be C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 Can be C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 Can be C-[(L 23 ) b23 -(R 23 ) c23 ], X 31 Can be C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 Can be C-[(L 32 ) b32 -(R 32) c32 ], X 33 Can be C-[(L 33 ) b33 -(R 33 ) c33 ], X 41 Can be C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 Can be C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 Can be C-[(L 43 ) b43 -(R 43 ) c43 ], X 44 Can be C-[(L 44 ) b44 -(R 44 ) c44 ],

[0551] X 51 Can be O, S, or N-[(L 7 ) b7 -(R 7 ) c7 ],

[0552] b7 can be 0, c7 can be 1,

[0553] R 7 You can choose from:

[0554] C 1 -C 30 Alkyl; and

[0555] C substituted by at least one selected from the following 1 -C 30 Alkyl: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 10 Alkyl, C 1 -C 10alkoxy, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, norbornenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, phenyl, naphthyl, pyridinyl and pyrimidinyl,

[0556] R 11 -R 14 , R 21 -R 23 , R 31 -R 33 and R 41 -R 44 can be independently selected from hydrogen, deuterium, -F, cyano, nitro, -SF 5 、-CH 3 、-CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , groups represented by formulae 9-1 to 9-19, groups represented by formulae 10-1 to 10-167, -N(Q 1 )(Q 2 )、-Si(Q 3 )(Q 4 )(Q 5 )、-B(Q 6 )(Q 7 ) and -P(=O)(Q 8 )(Q 9 )(where Q 1 -Q 9 each independently the same as described herein), and

[0557] In Formula 1-1, R 11 -R 14 , R 21 -R 23 , R 31 -R 33 and R 41 -R 44 At least one of may be each independently selected from groups represented by Formulae 10-1 to 10-167, but the embodiments of the present disclosure are not limited thereto.

[0558] For example, the organometallic compound may be one selected from compounds 1-1 to 1-88, compounds 2-1 to 2-47, and compounds 3-1 to 3-582, but embodiments of the present disclosure are not limited thereto:

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593] Formula 1A comprises CY 5 The 5-membered ring represented by Formula 1A includes CY in Formula 1A as a 6-membered ring. 5 CY 2 CY 3 and M form a cyclometallated ring (see Formula 1A'). Therefore, a stable bond angle can be formed between the tetradentate ligand and the metal in Formula 1A, thereby improving the molecular stability of the organometallic compound represented by Formula 1A:

[0594] <Formula 1A'>

[0595]

[0596] In Formula 1A, i) M is Pt, ii) X 1 O, iii)X 2 and X 4 Each is N, X 3 For C, in X 2 and M and the bond between X 4 The bonds between X and M are each coordination bonds, and 3 The bond between Y and M is a covalent bond, iv) 1 and Y 3 -Y 5 Each is C, v) in Y 5 and X 51 The key between 3 and X 51 The bonds between are each single bonds, vi)CY 1 CY 2 and CY 3 Each is a phenyl group, and CY 4 is a pyridine group, vii) X 51 O, S, or N-[(L 7 ) b7 -(R 7 ) c7], and viii) b7 is 0, c7 is 1, and R 7 is substituted or unsubstituted C 1 -C 60 In the case of alkyl, a1-a4 can be independently 1, 2, 3, 4 or 5 and are selected from R 1 -R 4 At least one of which may be selected from substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkenyl, substituted or unsubstituted C 1 -C 10 Heterocycloalkenyl, substituted or unsubstituted C 6 -C 60 Aryl, substituted or unsubstituted C 1 -C 60 Heteroaryl, substituted or unsubstituted monovalent non-aromatic fused polycyclic group, and substituted or unsubstituted monovalent non-aromatic fused heteropolycyclic group. Therefore, the organometallic compound represented by Formula 1A can have improved molecular orientation (orientation), and in this regard, electronic devices such as organic light-emitting devices including the organometallic compound represented by Formula 1A can have improved efficiency and lifespan.

[0597] X in Formula 1A 4 may be N. Therefore, the organometallic compound represented by Formula 1A may emit phosphorescent light emission having high luminous efficiency due to an intermolecular charge transfer mechanism.

[0598] In addition, CY in Formula 1A 4 It cannot be a benzimidazole group. In one embodiment, CY in Formula 1A 4 may be selected from a) a 6-membered ring, b) a condensed ring having two or more 6-membered rings condensed to each other, and c) a condensed ring having one 5-membered ring and two or more 6-membered rings condensed to each other, wherein the 6-membered ring may be selected from a cyclohexane group, a cyclohexene group, an adamantane group, a norbornane group, a norbornene group, a phenyl group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, and a triazine group, and the 5-membered ring may be selected from a cyclopentane group, a cyclopentene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, Azole group, iso azole group, thiazole group, isothiazole group, oxadiazole group and thiadiazole group. Therefore, the organometallic compound represented by Formula 1A may emit phosphorescent light emission with high luminous efficiency due to an intermolecular charge transfer mechanism.

[0599] For example, the highest occupied molecular orbital (HOMO) energy level, the lowest unoccupied molecular orbital (LUMO) energy level, the singlet state (S) energy level, and the molecular structure of each of compounds 1-28, 1-30, 1-17, 1-9, and 1-12 were evaluated by using the density functional theory (DFT) method of the Gaussian program (the structure was optimized at the B3LYP, 6-31G (d, p) level). 1 ) energy level and triplet state (T 1 The evaluation results are shown in Table 1.

[0600] [Table 1]

[0601]

[0602]

[0603] Referring to Table 1, it was confirmed that the organometallic compound represented by Formula 1A had electrical characteristics suitable for use as a dopant for electronic devices such as organic light-emitting devices.

[0604] The synthesis method of the organometallic compound represented by Formula 1A may be recognized by a person of ordinary skill in the art by referring to the synthesis examples provided below.

[0605] The organometallic compound represented by Formula 1A is suitable for use in an organic layer of an organic light-emitting device, for example, as a dopant in an emission layer of the organic layer. Therefore, another aspect of the present disclosure provides an organic light-emitting device comprising: a first electrode; a second electrode; and an organic layer disposed between the first electrode and the second electrode and comprising an emission layer, wherein the organic layer comprises at least one of the organometallic compounds represented by Formula 1A.

[0606] Due to including the organic layer including the organometallic compound represented by Formula 1A, the organic light emitting device may have low driving voltage, high efficiency, high power, high quantum efficiency, long lifespan, low roll-off ratio, and excellent color purity.

[0607] The organic metal compound represented by Formula 1A can be used between the electrode pairs of the organic light-emitting device. For example, the organic metal compound represented by Formula 1A can be included in the emission layer. In this regard, the organic metal compound can act as a dopant, and the emission layer can further include a host (i.e., the amount of the organic metal compound represented by Formula 1A is less than the amount of the host).

[0608] The expression “(organic layer) includes at least one of the organic metal compounds” used herein may include the case where “(organic layer) includes the same organic metal compound represented by Formula 1A” and the case where “(organic layer) includes two or more different organic metal compounds represented by Formula 1A”.

[0609] For example, the organic layer may include only compound 1-1 as the organic metal compound. In this regard, compound 1-1 may be present in the emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include compound 1-1 and compound 1-2 as the organic metal compound. In this regard, compound 1-1 and compound 1-2 may be present in the same layer (for example, compound 1-1 and compound 1-2 may all be present in the emission layer).

[0610] The first electrode may be an anode as a hole injection electrode, and the second electrode may be a cathode as an electron injection electrode; or the first electrode may be a cathode as an electron injection electrode, and the second electrode may be an anode as a hole injection electrode.

[0611] For example, in the organic light-emitting device, the first electrode may be an anode, and the second electrode may be a cathode, and the organic layer may further include a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode, and the hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and the electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0612] The term "organic layer" as used herein refers to a single layer and / or a plurality of layers between a first electrode and a second electrode of the organic light emitting device. In addition to the organic compound, the "organic layer" may include an organic metal complex including a metal.

[0613] Figure 1 FIG. 1 is a schematic diagram of an organic light emitting device 10 according to an embodiment. Figure 1 The structure of an organic light emitting device according to an embodiment and a method of manufacturing the organic light emitting device according to an embodiment are described. The organic light emitting device 10 includes a first electrode 11 , an organic layer 15 , and a second electrode 19 which are sequentially stacked.

[0614] A substrate may be additionally provided under the first electrode 11 or over the second electrode 19. For use as a substrate, any substrate used in a general organic light-emitting device may be used, and the substrate may be a glass substrate or a transparent plastic substrate each having excellent mechanical strength, thermal stability, transparency, surface smoothness, easy handling, and water resistance.

[0615] The first electrode 11 can be formed by depositing or sputtering a material for forming the first electrode 11 on the substrate. The first electrode 11 can be an anode. The material for forming the first electrode 11 can be selected from materials having a high work function to facilitate hole injection. The first electrode 11 can be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode can be, for example, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO 2 ) and zinc oxide (ZnO). In one or more embodiments, magnesium (Mg), aluminum (Al), aluminum-lithium (Al-Li), calcium (Ca), magnesium-indium (Mg-In), or magnesium-silver (Mg-Ag) may be used as a material for forming the first electrode.

[0616] The first electrode 11 may have a single-layer structure or a multi-layer structure including two or more layers. For example, the first electrode 11 may have a three-layer structure of ITO / Ag / ITO, but the structure of the first electrode 110 is not limited thereto.

[0617] The organic layer 15 is provided on the first electrode 11 .

[0618] The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.

[0619] The hole transport region may be disposed between the first electrode 11 and the emission layer.

[0620] The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

[0621] The hole transport region may include only a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer / hole transport layer structure or a hole injection layer / hole transport layer / electron blocking layer structure, which are sequentially stacked in the stated order starting from the first electrode 11.

[0622] The hole injection layer may be formed on the first electrode 11 by using one or more suitable methods selected from vacuum deposition, spin coating, casting, or Langmuir-Blodgett (LB) deposition.

[0623] When the hole injection layer is formed by vacuum deposition, the deposition conditions may vary depending on the compound used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. For example, the deposition conditions may include a deposition temperature of about 100° C. to 500° C., a ... -8 - Approx. 10 -3 Torr vacuum pressure and However, the deposition conditions are not limited thereto.

[0624] When the hole injection layer is formed using spin coating, the coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, the coating speed may be about 2000 rpm to about 5000 rpm, and the temperature of heat treatment to remove the solvent after coating may be about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

[0625] The conditions for forming the hole transport layer and the electron blocking layer can be understood by referring to the conditions for forming the hole injection layer.

[0626] The hole transport region may include at least one selected from the group consisting of m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, spiro-TPD, spiro-NPB, methylated NPB, TAPC, HMTPD, 4,4',4"-tri(N-carbazolyl)triphenylamine (TCTA), polyaniline / dodecylbenzenesulfonic acid (PANI / DBSA), poly(3,4-ethylenedioxythiophene) / poly(4-styrenesulfonate) (PEDOT / PSS), polyaniline / camphorsulfonic acid (PANI / CSA), polyaniline / poly(4-styrenesulfonate) (PANI / PSS), a compound represented by the following Formula 201, and a compound represented by the following Formula 202:

[0627]

[0628]

[0629] <Formula 201>

[0630]

[0631] <Formula 202>

[0632]

[0633] In formula 201, Ar 101 and Ar 102 Can be independently selected from:

[0634] Phenylene, cyclopentadienylene, indenylene, naphthylene, azulenylene, heptalenylene, acenaphthenylene, fluorenylene, phenanthrenylene, anthracenylene, fluoranthenylene, benzo[9,10]phenanthrenylene, pyren ... phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene, phenanthrenylene phenylene, tetraphenylene, perylenene, and pentacene; and

[0635] Each of the following is selected from at least one substituted phenylene, pentalene, indenylene, naphthylene, azulenylene, heptalene, acenaphthene, fluorenylene, phenanthrenylene, anthracenylene, fluoranthenylene, benzo[9,10]phenanthrenylene, pyrenyl ... phenanthrenylene, fluorenylene, benzo[9,10]phenan phenylene, tetraphenylene, perylene, perylene and pentphenylene: deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, a monovalent non-aromatic fused polycyclic group, and a monovalent non-aromatic fused heteropolycyclic group.

[0636] In Formula 201, xa and xb may each independently be an integer of 0 to 5, or may each independently be 0, 1, or 2. For example, xa may be 1 and xb may be 0, but embodiments of the present disclosure are not limited thereto.

[0637] In equations 201 and 202, R 101 -R 108 , R 111 -R 119 and R 121 -R 124 Can be independently selected from:

[0638] hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 10 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, etc.), and C 1 -C10 Alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy, etc.);

[0639] Each of the following is substituted by at least one C 1 -C 10 Alkyl and C 1 -C 10 Alkoxy: deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, and phosphoric acid group or its salt;

[0640] phenyl, naphthyl, anthracenyl, fluorenyl and pyrenyl; and

[0641] phenyl, naphthyl, anthracenyl, fluorenyl and pyrenyl, each of which is selected from at least one substituted group consisting of deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid group or salt thereof, sulfonic acid group or salt thereof, phosphoric acid group or salt thereof, C 1 -C 10 Alkyl and C 1 -C 10 Alkoxy;

[0642] However, the implementation of the present disclosure is not limited thereto.

[0643] In formula 201, R 109 You can choose from:

[0644] phenyl, naphthyl, anthracenyl, and pyridyl; and

[0645] phenyl, naphthyl, anthracenyl and pyridyl groups each selected from at least one substituted group consisting of deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid or salt thereof, sulfonic acid or salt thereof, phosphoric acid or salt thereof, C 1 -C 20 Alkyl, C 1 -C 20 Alkoxy, phenyl, naphthyl, anthracenyl and pyridyl.

[0646] In one embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:

[0647] <Formula 201A>

[0648]

[0649] In Formula 201A, R 101 , R 111 , R 112 and R 109This can be understood by referring to the description provided herein.

[0650] For example, the compound represented by Formula 201 and the compound represented by Formula 202 may include the following compounds HT1 to HT20, but embodiments of the present disclosure are not limited thereto:

[0651]

[0652]

[0653] The thickness of the hole transport region may be For example When the hole transport region includes at least one of a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be in the range of For example In the range of, and the thickness of the hole transport layer can be For example When the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transport characteristics may be obtained without a significant increase in driving voltage.

[0654] In addition to these materials, the hole transport region may further include a charge generating material for improving conductive properties. The charge generating material may be uniformly or non-uniformly dispersed in the hole transport region.

[0655] The charge generating material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a compound containing a cyano group, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are quinone derivatives such as tetracyanoquinodimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinodimethane (F4-TCNQ); metal oxides such as tungsten oxide or molybdenum oxide; and compounds containing a cyano group such as the following compound HT-D1 or compound HT-D2, but embodiments of the present disclosure are not limited thereto:

[0656]

[0657] The hole transport region may include a buffer layer.

[0658] The buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of the formed organic light emitting device may be improved.

[0659] Then, an emission layer may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, etc. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those used to form the hole injection layer, although the deposition or coating conditions may vary depending on the material used to form the emission layer.

[0660] Meanwhile, when the hole transport region includes an electron blocking layer, the material for the electron blocking layer may be selected from the materials for the hole transport region described above and the materials for the host to be described later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, the material for the electron blocking layer may be mCP, which will be described later.

[0661] The emission layer may include a host and a dopant, and the dopant may include an organic metal compound represented by Formula 1A.

[0662] The host may include at least one selected from TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:

[0663]

[0664] In one or more embodiments, the host may further include a compound represented by the following formula 301:

[0665] <Formula 301>

[0666]

[0667] In formula 301, Ar 111 and Ar 112 Can be independently selected from:

[0668] Phenylene, naphthylene, phenanthrenyl and pyrenylene; and

[0669] Phenylene, naphthylene, phenanthrenylene and pyrenylene, each of which is substituted by at least one selected from the group consisting of phenyl, naphthyl and anthracenyl.

[0670] In formula 301, Ar 113 -Ar 116 Can be independently selected from:

[0671] C 1 -C 10 alkyl, phenyl, naphthyl, phenanthrenyl, and pyrenyl; and

[0672] Phenyl, naphthyl, phenanthrenyl and pyrenyl, each of which is substituted by at least one selected from the group consisting of phenyl, naphthyl and anthracenyl.

[0673] In Formula 301, g, h, i, and j may each independently be an integer of 0-4, for example, 0, 1, or 2.

[0674] In formula 301, Ar 113 -Ar 116 Can be independently selected from:

[0675] C substituted by at least one selected from phenyl, naphthyl and anthracenyl 1 -C 10 alkyl;

[0676] phenyl, naphthyl, anthracenyl, pyrenyl, phenanthrenyl and fluorenyl;

[0677] phenyl, naphthyl, anthracenyl, pyrenyl, phenanthrenyl and fluorenyl, each of which is selected from at least one substituted group consisting of deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amino, amidino, hydrazine, hydrazone, carboxylic acid group or salt thereof, sulfonic acid group or salt thereof, phosphoric acid group or salt thereof, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, phenyl, naphthyl, anthracenyl, pyrenyl, phenanthrenyl, and fluorenyl; and

[0678]

[0679] However, the implementation of the present disclosure is not limited thereto.

[0680] In one or more embodiments, the host may include a compound represented by Formula 302:

[0681] <Formula 302>

[0682]

[0683] In formula 302, Ar 122 -Ar 125 With respect to Ar in Formula 301 113 Same as described in detail.

[0684] In formula 302, Ar 126 and Ar 127 Can be independently C 1 -C 10 Alkyl (eg, methyl, ethyl, or propyl).

[0685] In formula 302, k and l may each independently be an integer of 0 to 4. For example, k and l may be 0, 1, or 2.

[0686] The compound represented by Formula 301 and the compound represented by Formula 302 may include the following compounds H1 to H42, but embodiments of the present disclosure are not limited thereto.

[0687]

[0688]

[0689]

[0690] When the organic light emitting device is a full-color organic light emitting device, the emission layer can be patterned into a red emission layer, a green emission layer and a blue emission layer. In one or more embodiments, the emission layer can emit white light due to the stacked structure including the red emission layer, the green emission layer and / or the blue emission layer.

[0691] When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

[0692] The thickness of the emission layer may be For example When the thickness of the emission layer is within this range, excellent light emitting characteristics can be obtained without a significant increase in driving voltage.

[0693] Then, an electron transport region may be disposed on the emission layer.

[0694] The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0695] For example, the electron transport region may have a hole blocking layer / electron transport layer / electron injection layer structure or an electron transport layer / electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single layer structure or a multilayer structure including two or more different materials.

[0696] The conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer constituting the electron transport region may be understood by referring to the conditions for forming the hole injection layer.

[0697] When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, and BAlq, but embodiments of the present disclosure are not limited thereto:

[0698]

[0699] The thickness of the hole blocking layer can be For example When the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have improved hole blocking capability without a significant increase in driving voltage.

[0700] The electron transport layer may further include BCP, Bphen, Alq 3 , BAlq, TAZ and NTAZ:

[0701]

[0702] In one or more embodiments, the electron transport layer may include at least one of compounds ET1 to ET25, but embodiments of the present disclosure are not limited thereto:

[0703]

[0704]

[0705]

[0706] The thickness of the electron transport layer can be For example When the thickness of the electron transport layer is within the above range, the electron transport layer may have satisfactory electron transport characteristics without a significant increase in driving voltage.

[0707] In addition, the electron transport layer may further include a material including a metal in addition to the above-mentioned materials.

[0708] The metal-containing material may include a Li complex. The Li complex may include, for example, compound ET-D1 (8-hydroxyquinoline lithium, LiQ) or compound ET-D2:

[0709]

[0710] The electron transport region may include an electron injection layer that facilitates the flow of electrons from the second electrode 19 thereinto.

[0711] The electron injection layer may include a material selected from LiF, NaCl, CsF, Li 2 At least one of O, and BaO.

[0712] The thickness of the electron injection layer can be For example When the thickness of the electron injection layer is within the above range, the electron injection layer may have satisfactory electron injection characteristics without a significant increase in driving voltage.

[0713] A second electrode 19 is provided on the organic layer 15. The second electrode 19 may be a cathode. The material for forming the second electrode 19 may be selected from metals, alloys, conductive compounds, and combinations thereof having a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al-Li), calcium (Ca), magnesium-indium (Mg-In), or magnesium-silver (Mg-Ag) may be used as the material for forming the second electrode 19. In one or more embodiments, in order to manufacture a top-emitting light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode 19.

[0714] In the above, reference has been made to Figure 1 An organic light emitting device is described, but embodiments of the present disclosure are not limited thereto.

[0715] Another aspect of the present disclosure provides a diagnostic composition comprising at least one organometallic compound represented by Formula 1A.

[0716] The organometallic compound represented by Formula 1 provides high luminescence efficiency. Therefore, a diagnostic composition including the organometallic compound may have high diagnostic efficiency.

[0717] The diagnostic compositions can be used in a variety of applications including diagnostic kits, diagnostic reagents, biosensors, and biomarkers.

[0718] As used herein, the term "C 1 -C 60 "Alkyl" refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and non-limiting examples thereof include methyl, ethyl, propyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl and hexyl. The term "C 1 -C 60 "Alkylene" refers to a group having a C 1 -C 60 Alkyl is a divalent group of the same structure.

[0719] As used herein, the term "C 1 -C 60 "Alkoxy" refers to -OA 101 The monovalent group represented by 101 C 1 -C 60 alkyl), and non-limiting examples thereof include methoxy, ethoxy, and isopropoxy.

[0720] As used herein, the term "C 2 -C 60 "Alkenyl" refers to a 2 -C 60The term "C" as used herein refers to a hydrocarbon group formed by inserting at least one carbon-carbon double bond in the middle or at the terminal of an alkyl group, and examples thereof include ethenyl, propenyl and butenyl. 2 -C 60 "Alkenylene" refers to a 2 -C 60 Alkenyl is a divalent group of the same structure.

[0721] As used herein, the term "C 2 -C 60 "Alkynyl" refers to a 2 -C 60 The term "C" as used herein refers to a hydrocarbon group formed by inserting at least one carbon-carbon triple bond into the middle or terminal of an alkyl group, and examples thereof include ethynyl and propynyl. 2 -C 60 "Alkyne" refers to a 2 -C 60 Alkynyl is a divalent group of the same structure.

[0722] As used herein, the term "C 3 -C 10 "Cycloalkyl" refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. As used herein, the term "Cycloalkyl" refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 3 -C 10 "Cycloalkylene" refers to a cycloalkylene group having a 3 -C 10 Cycloalkyl is a divalent group of the same structure.

[0723] As used herein, the term "C 1 -C 10 "Heterocycloalkyl" refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring atom and 1 to 10 carbon atoms, and non-limiting examples thereof include tetrahydrofuranyl and tetrahydrothienyl. As used herein, the term "C 1 -C 10 "Heterocycloalkylene" refers to a group having a C 1 -C 10 Heterocycloalkyl is a divalent group of the same structure.

[0724] As used herein, the term "C 3 -C 10 "Cycloalkenyl" refers to a monovalent monocyclic group having 3 to 10 carbon atoms and at least one carbon-carbon double bond in its ring and not having aromaticity, and non-limiting examples thereof include cyclopentenyl, cyclohexenyl and cycloheptenyl. As used herein, the term "C 3 -C 10 "Cycloalkenylene" refers to a3 -C 10 Cycloalkenyl is a divalent group of the same structure.

[0725] As used herein, the term "C 1 -C 10 The term "heterocycloalkenyl" refers to a monovalent monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. 1 -C 10 Examples of heterocycloalkenyl are 2,3-dihydrofuranyl and 2,3-dihydrothienyl. 1 -C 10 "Heterocycloalkenylene" refers to a 1 -C 10 Heterocycloalkenyl is a divalent group of the same structure.

[0726] As used herein, the term "C 6 -C 60 "Aryl" refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term "C 6 -C 60 "Arylene" refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. 6 -C 60 Non-limiting examples of aryl groups include phenyl, naphthyl, anthracenyl, phenanthrenyl, pyrenyl, and When C 6 -C 60 Aryl and C 6 -C 60 When the arylene groups each include two or more rings, the rings may be fused to each other.

[0727] As used herein, the term "C 1 -C 60 "Heteroaryl" refers to a monovalent group having an aromatic system having at least one heteroatom selected from N, O, P and S as a ring atom and 1 to 60 carbon atoms. The term "C 1 -C 60 The term "heteroarylene" refers to a divalent group having an aromatic system having at least one heteroatom selected from N, O, P and S as a ring atom and 1 to 60 carbon atoms. 1 -C 60 Non-limiting examples of heteroaryl groups include pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, and isoquinolinyl. 1 -C 60 Heteroaryl and C 1 -C60 When the heteroarylene groups each include two or more rings, the rings may be fused to each other.

[0728] The term "C 6 -C 60 "Aryloxy" means -OA 102 (A 102 C 6 -C 60 aryl), and C 6 -C 60 Arylthio represents -SA 103 (A 103 C 6 -C 60 aryl).

[0729] As used herein, the term "monovalent non-aromatic fused polycyclic group" refers to a monovalent group (e.g., having 8 to 60 carbon atoms) having two or more rings fused to each other, having only carbon atoms as ring-forming atoms, and having non-aromaticity in terms of the entire molecular structure. Examples of the monovalent non-aromatic fused polycyclic group include fluorenyl. The term "divalent non-aromatic fused polycyclic group" as used herein refers to a divalent group having the same structure as the monovalent non-aromatic fused polycyclic group.

[0730] The term "monovalent non-aromatic fused heteropolycyclic group" as used herein refers to a monovalent group (e.g., having 2-60 carbon atoms) having two or more rings fused to each other, having a heteroatom selected from N, O, P, Si and S as a ring-forming atom in addition to carbon atoms, and having non-aromaticity in terms of the entire molecular structure. Non-limiting examples of the monovalent non-aromatic fused heteropolycyclic group include carbazolyl. The term "divalent non-aromatic fused heteropolycyclic group" as used herein refers to a divalent group having the same structure as the monovalent non-aromatic fused heteropolycyclic group.

[0731] As used herein, the term "C 5 -C 30 The term "carbocyclic group" refers to a saturated or unsaturated cyclic group having only 5 to 30 carbon atoms as ring atoms. 5 -C 30 The carbocyclic group may be a monocyclic group or a polycyclic group.

[0732] As used herein, the term "C 1 -C 30 The term "heterocyclic group" refers to a saturated or unsaturated cyclic group having at least one heteroatom selected from N, O, Si, P and S as a ring atom in addition to 1 to 30 carbon atoms. 1 -C 30The heterocyclic group may be a monocyclic group or a polycyclic group.

[0733] Substituted C 5 -C 30 Carbocyclic groups, substituted C 2 -C 30 Heterocyclic groups, substituted C 1 -C 60 Alkyl, substituted C 2 -C 60 Alkenyl, substituted C 2 -C 60 Alkynyl, substituted C 1 -C 60 Alkoxy, substituted C 3 -C 10 Cycloalkyl, substituted C 1 -C 10 Heterocycloalkyl, substituted C 3 -C 10 Cycloalkenyl, substituted C 1 -C 10 Heterocycloalkenyl, substituted C 6 -C 60 Aryl, substituted C 6 -C 60 Aryloxy, substituted C 6 -C 60 Arylthio, substituted C 1 -C 60 At least one substituent of the heteroaryl group, the substituted monovalent non-aromatic fused polycyclic group, and the substituted monovalent non-aromatic fused heteropolycyclic group may be selected from:

[0734] Deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy;

[0735] Each of the following is substituted by at least one C 1 -C 60 Alkyl, C 2 -C60 Alkenyl, C 2 -C 60 Alkynyl and C 1 -C 60 Alkoxy: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 11 )(Q 12 )、-Si(Q 13 )(Q 14 )(Q 15 )、-B(Q 16 )(Q 17 ) and -P(=O)(Q 18 )(Q 19 );

[0736] C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups;

[0737] Each of the following is substituted by at least one C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 Heteroaryl, monovalent non-aromatic fused polycyclic group, and monovalent non-aromatic fused heteropolycyclic group: deuterium, -F, -Cl, -Br, -I, -CD 3 、-CD 2 H.-CDH 2 , -CF 3 , -CF 2 H, -CFH 2 , hydroxyl, cyano, nitro, amino, amidine, hydrazine, hydrazone, carboxylic acid or its salt, sulfonic acid or its salt, phosphoric acid or its salt, C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl, monovalent non-aromatic fused polycyclic group, monovalent non-aromatic fused heteropolycyclic group, -N(Q 21 )(Q 22 )、-Si(Q 23)(Q 24 )(Q 25 )、-B(Q 26 )(Q 27 ) and -P(=O)(Q 28 )(Q 29 );and

[0738] -N(Q 31 )(Q 32 )、-Si(Q 33 )(Q 34 )(Q 35 )、-B(Q 36 )(Q 37 ) and -P(=O)(Q 38 )(Q 39 ),and

[0739] Q 1 -Q 9 , Q 11 -Q 19 , Q 21 -Q 29 and Q 31 -Q 39 can be independently selected from hydrogen, deuterium, -F, -Cl, -Br, -I, hydroxyl, cyano, nitro, amidine, hydrazine, hydrazone, carboxylic acid group or its salt, sulfonic acid group or its salt, phosphoric acid group or its salt, C 1 -C 60 Alkyl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 1 -C 60 Alkyl, C 2 -C 60 Alkenyl, C 2 -C 60 Alkynyl, C 1 -C 60 Alkoxy, C 3 -C 10 Cycloalkyl, C 1 -C 10 Heterocycloalkyl, C 3 -C 10 Cycloalkenyl, C 1 -C 10 Heterocycloalkenyl, C 6 -C 60 Aryl, selected from deuterium, C 1 -C 60 Alkyl and C 6 -C 60 At least one substituted C 6-C 60 Aryl, C 6 -C 60 Aryloxy, C 6 -C 60 Arylthio, C 1 -C 60 heteroaryl groups, monovalent non-aromatic fused polycyclic groups, and monovalent non-aromatic fused heteropolycyclic groups.

[0740] Hereinafter, the compound and the organic light-emitting device according to the embodiment are described in detail with reference to the synthesis examples and the examples. However, the organic light-emitting device is not limited thereto. The phrase "using B instead of A" used in describing the synthesis examples means that the amount of A used is equal to the amount of B used in terms of molar equivalents.

[0741] [Example]

[0742] Synthesis Example 1: Synthesis of Compound 1-1

[0743]

[0744] Intermediate A (2-(5-bromo-3',5'-di-tert-butyl-[1,1'-biphenyl]-3-yl)-4,4,5,5-tetramethyl-1,3, Synthesis of 2-dioxaborolane

[0745] 10 g (0.024 mol) of 3,5-dibromo-3',5'-di-tert-butyl-1,1'-biphenyl and 9.0 g (0.036 mol, 1.5 eq) of bis-pinacol diboron were added to the flask, and 4.6 g (0.048 mol, 2 eq) of potassium acetate and 0.96 g (0.05 eq) of PdCl 2 (dppf) was added to a flask. Then, 100 ml of toluene was added thereto, and the resulting mixture was refluxed overnight at a temperature of 100° C. The refluxed mixture thus obtained was cooled to room temperature, and the precipitate was filtered out therefrom. The precipitate was removed by using ethyl acetate (EA) / H 2 The filtrate obtained therefrom was washed with 0 and subjected to column chromatography to obtain 5.6 g (yield: 50%) of Intermediate A. The obtained product was confirmed by mass spectrometry and HPLC analysis.

[0746] For C 26 H 36 BBr 2 Calculated HRMS (MALDI): m / z 470.1992, Found: 470.1994

[0747] Synthesis of Intermediate B (2-(5-bromo-3',5'-di-tert-butyl-[1,1'-biphenyl]-3-yl)pyridine)

[0748] 5.6 g (0.014 mol, 1.2 equivalents) of intermediate A, 1.9 g (0.012 mol, 1 equivalent) of 2-bromopyridine, 0.61 g (0.001 mol, 0.07 equivalent) of tetrakis(triphenylphosphine)palladium(0), and 3.1 g (0.036 mol, 3 equivalents) of potassium carbonate were dissolved in tetrahydrofuran (THF) and distilled water (H 2 0) in a solvent (25 mL, 0.8 M) mixed in a volume ratio of 3:1, and the mixed solution was refluxed for 12 hours. The refluxed mixture thus obtained was cooled to room temperature, and the precipitate was filtered out therefrom. The reaction mixture was stirred for 12 hours using EA / H 2 The filtrate obtained therefrom was washed with 0 and subjected to column chromatography (while increasing the volume ratio of dichloromethane (MC) / hexane (Hex) to between 25% and 50%) to obtain 4 g (yield: 80%) of Intermediate B. The obtained product was confirmed by mass spectrometry and HPLC analysis.

[0749] For C 25 H 28 HRMS (MALDI) calculated for BrN: m / z 421.1405, found: 421.1407

[0750] Intermediate C (2-(3',5'-di-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- Synthesis of 1-[(1,1'-biphenyl)-3-yl)pyridine

[0751] 4 g (0.009 mol) of intermediate B (2-(5-bromo-3',5'-di-tert-butyl-[1,1'-biphenyl]-3-yl)pyridine) and 3.6 g (0.014 mol, 1.5 eq.) of bis-pinacolatodiboron were added to the flask, and 1.9 g (0.019 mol, 2 eq.) of potassium acetate and 0.39 g (0.05 eq.) of PdCl were added. 2 (dppf) was added to a flask. Then, 32 mL of toluene was added thereto, and the resulting mixture was refluxed overnight at a temperature of 100° C. The refluxed mixture thus obtained was cooled to room temperature, and the precipitate was filtered out therefrom. The precipitate was removed by using EA / H 2 The filtrate obtained therefrom was washed with 0, and subjected to column chromatography to obtain 2.4 g (yield: 56%) of Intermediate C. The obtained product was confirmed by analysis by mass spectrometry and HPLC.

[0752] For C 31 H 40 BNO 2 Calculated HRMS (MALDI): m / z 469.3152, Found: 469.3155

[0753] Intermediate E (2-(4-(3',5'-di-tert-butyl-5-(pyridin-2-yl)-[1,1'-biphenyl]-3-yl)-1-methyl- Synthesis of 1H-benzo[d]imidazol-2-yl)phenol

[0754] 2.4 g (0.005 mol, 1.2 equivalents) of intermediate C, 1.3 g (0.004 mol, 1 equivalent) of compound D (2-(4-bromo-1-methyl-1H-benzo[d]imidazol-2-yl)phenol), 0.35 g (0.001 mol, 0.07 equivalents) of tetrakis(triphenylphosphine)palladium(0), and 1.8 g (0.013 mol, 3 equivalents) of potassium carbonate were dissolved in tetrahydrofuran (THF) and distilled water (H 2 (20 mL) of a 3:1 volume ratio of solvent was added, and the mixed solution was refluxed for 12 hours. The refluxed mixture thus obtained was cooled to room temperature, and the precipitate was filtered out therefrom. The precipitate was removed by using EA / H 2 The filtrate obtained therefrom was washed with 0 and subjected to column chromatography (while increasing the volume ratio of MC / Hex to between 25% and 50%) to obtain 1.7 g (yield: 73%) of Intermediate E. The obtained product was confirmed by mass spectrometry and HPLC analysis.

[0755] For C 39 H 39 N 3 O Calculated HRMS (MALDI): m / z 565.3093, Found: 565.3096

[0756] Synthesis of compound 1-1

[0757] 1.4 g (2.5 mmol) of intermediate E and 1.23 g (3 mmol, 1.2 equivalents) of K 2 PtCl 4 Dissolve 20 mL of AcOH and 5 mL of H 2 O mixed with 25 mL of solvent, and the mixed solution was refluxed for 16 hours. The refluxed mixture thus obtained was cooled to room temperature, and the precipitate was filtered out therefrom. The precipitate was dissolved in MC again and the mixture was refluxed by using H 2 O for washing. Then, it was subjected to column chromatography (MC 40%, EA 1%, Hex 59%) to obtain 0.7 g (purity: 99% or more) of compound 1-1. The obtained product was confirmed by mass spectrometry and HPLC analysis.

[0758] For C 39 H 37 N 3 HRMS (MALDI) calculated for OPt: m / z 758.26, measured: 758.26

[0759] Synthesis Example 2: Synthesis of Compound 1-28

[0760]

[0761] Synthesis of intermediate H

[0762] Intermediate H was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound F and Compound G were used instead of Compound D and Intermediate C, respectively.

[0763] For C 42 H 47 N 3 HRMS (MALDI) calculated for OSi: m / z 637.3488, found: 637.3485 Compound 1-28 synthesis

[0764] Compound 1-28 (1.5 g, yield: 52%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate H was used instead of Intermediate E.

[0765] For C 42 H 45 N 3 HRMS (MALDI) calculated for OPtSi: m / z 830.2980, found: 830.2983

[0766] Synthesis Example 3: Synthesis of Compound 1-30

[0767]

[0768] Synthesis of Intermediate J

[0769] Intermediate J was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound F and Compound I were used instead of Compound D and Intermediate C, respectively.

[0770] For C 40 H 41 N 3 O Calculated HRMS (MALDI): m / z 579.3250, Found: 579.3252

[0771] Synthesis of Compound 1-30

[0772] Compound 1-30 (1.2 g, yield: 56%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate J was used instead of Intermediate E.

[0773] For C 40 H 39 N 3 HRMS (MALDI) calculated for OPt: m / z 772.2741, measured: 772.2745

[0774] Synthesis Example 4: Synthesis of Compound 1-17

[0775]

[0776] Synthesis of intermediate L

[0777] Intermediate L was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound F and Compound K were used instead of Compound D and Intermediate C, respectively.

[0778] For C 46 H 45 N 3 O Calculated HRMS (MALDI): m / z 655.3563, Found: 655.3567

[0779] Synthesis of Compound 1-17

[0780] Compound 1-17 (1.7 g, yield: 57%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate L was used instead of Intermediate E.

[0781] For C 46 H 43 N 3 HRMS (MALDI) calculated for OPt: m / z 848.3054, measured: 848.3053

[0782] Synthesis Example 5: Synthesis of Compound 1-9

[0783]

[0784] Synthesis of Intermediate N

[0785] Intermediate N was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound F and Compound M were used instead of Compound D and Intermediate C, respectively.

[0786] For C 48 H 51 N 3 HRMS (MALDI) calculated for OSi: m / z 713.3801, found: 713.3804

[0787] Synthesis of Compounds 1-9

[0788] Compound 1-9 (1.2 g, yield: 52%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate N was used instead of Intermediate E.

[0789] For C 48 H 49 N 3 HRMS (MALDI) calculated for OPtSi: m / z 906.3293, found: 906.3297

[0790] Synthesis Example 6: Synthesis of Compound 1-12

[0791]

[0792] Synthesis of intermediate R

[0793] Intermediate R was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound F and Compound Q were used instead of Compound D and Intermediate C, respectively.

[0794] For C 45 H 43 N 3 O Calculated HRMS (MALDI): m / z 641.3406, Found: 641.3408

[0795] Synthesis of Compounds 1-12

[0796] Compound 1-12 (1.0 g, yield: 45%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate R was used instead of Intermediate E.

[0797] For C 45 H 41 N 3 HRMS (MALDI) calculated for OPt: m / z 834.2897, measured: 834.2892

[0798] Synthesis Example 7: Synthesis of Compound 3-417

[0799]

[0800] Synthesis of Intermediate U

[0801] Intermediate U was synthesized in the same manner as for the synthesis of Intermediate E in Synthesis Example 1, except that Compound S and Compound T were used instead of Compound D and Intermediate C, respectively.

[0802] For C 51 H 49 N 3 O Calculated HRMS (MALDI): m / z 719.3876, Found: 719.3874

[0803] Synthesis of Compound 3-417

[0804] Compound 3-417 (1.2 g, yield: 55%) was synthesized in the same manner as used to synthesize Compound 1-1 in Synthesis Example 1, except that Intermediate U was used instead of Intermediate E.

[0805] For C 45 H 41 N 3 HRMS (MALDI) calculated for OPt: m / z 912.3367, measured: 912.3369

[0806] Example 1

[0807] The ITO glass substrate on which the ITO electrode (anode) was deposited was cut into a size of 50 mm×50 mm×0.5 mm, ultrasonically treated with acetone, isopropyl alcohol and pure water for 15 minutes each, and then cleaned by exposure to ultraviolet (UV) rays and ozone for 30 minutes.

[0808] Then, m-MTDATA is replaced with The deposition rate is deposited on the ITO electrode (anode) of the glass substrate to form a Then, α-NPD (also called NPB) is added to form a hole injection layer with a thickness of is deposited on the hole injection layer at a deposition rate of The hole transport layer has a thickness of .

[0809] Compound 1-28 (dopant) and CBP (host) were respectively and The deposition rate is co-deposited on the hole transport layer to form a The thickness of the emission layer.

[0810] Balq is deposited on the emission layer at a deposition rate of The thickness of the hole blocking layer is Alq 3 deposited on the hole blocking layer to form a An electron transport layer having a thickness of An electron injection layer having a thickness of , and Al is vacuum deposited on the electron injection layer to form A second electrode (cathode) with a thickness of , thereby completing the manufacture of an organic light-emitting device having the following structure: ITO / m-MTDATA / α-NPD / CBP+Compound 1-28 (10 wt%) / BAlq / Alq 3 / LiF / Al

[0811]

[0812] Examples 2-6 and Comparative Examples 1-4

[0813] Organic light-emitting devices were manufactured in the same manner as in Example 1, except that the compounds shown in Table 2 were each used as a dopant instead of Compounds 1 to 28 when forming the emission layer.

[0814] Evaluation Example 1: Evaluation of Characteristics of Organic Light-Emitting Device

[0815] The driving voltage, luminous efficiency, quantum emission efficiency, roll-off ratio, and lifespan (T 95 ) characteristics, and the results are shown in Table 2. The equipment used for evaluation was a current-voltage meter (Keithley 2400) and a brightness meter (Minolta Cs-1000A). Lifespan (T 95 ) (at 6000 nits) represents the amount of time that elapses when the luminance is 95% of the initial luminance (100%) in a relative manner relative to those of the organic light-emitting device of Example 6. The roll-off ratio is calculated according to <Equation 20>. The luminous efficiency is also provided in a relative manner relative to those of the organic light-emitting device of Example 5.

[0816] <Equation 20>

[0817] Roll-off ratio = {1-(efficiency at 9000 nits / maximum luminous efficiency)}×100%

[0818] [Table 2]

[0819]

[0820]

[0821] Referring to Table 2, it was confirmed that the organic light emitting devices of Examples 1-6 simultaneously had improved driving voltage, luminous efficiency, quantum emission efficiency, roll-off ratio, and lifespan characteristics compared to those of the organic light emitting devices of Comparative Examples 1-4.

[0822] As described above, the organometallic compound according to the embodiment of the present disclosure has excellent electrical properties and thermal stability, and therefore, the organic light-emitting device including the organometallic compound can have excellent driving voltage, luminous efficiency, quantum emission efficiency, roll-off ratio, and life characteristics. In addition, due to the excellent phosphorescent luminescence characteristics of the organometallic compound, the organometallic compound can provide a diagnostic composition with high diagnostic efficiency.

[0823] It should be understood that the embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

[0824] Although one or more embodiments have been described with reference to the drawings, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the following claims.

Claims

1. An organic metal compound represented by formula 1-1: <Formula 1-1> in, In formula 1-1, M is platinum (Pt), X1 is O or S, and the bond between X1 and M is a covalent bond, X2 is N, and X3 is C, The bond between X2 and M is a coordination bond, the bond between X3 and M is a covalent bond, and in the 41 -X 44 The bond between N and M in the ring is a coordination bond. X 51 N-[(L7) b7 -(R7) c7 ], X 11 C-[(L 11 ) b11 -(R 11 ) c11 ], X 12 C-[(L 12 ) b12 -(R 12 ) c12 ], X 13 C-[(L 13 ) b13 -(R 13 ) c13 ], X 14 C-[(L 14 ) b14 -(R 14 ) c14 ], X 21 C-[(L 21 ) b21 -(R 21 ) c21 ], X 22 C-[(L 22 ) b22 -(R 22 ) c22 ], X 23 C-[(L 23 ) b23 -(R 23 ) c23 ], X 31 C-[(L 31 ) b31 -(R 31 ) c31 ], X 32 C-[(L 32 ) b32 -(R 32 ) c32 ], X 33 C-[(L 33 ) b33 -(R 33 ) c33 ], X 41 C-[(L 41 ) b41 -(R 41 ) c41 ], X 42 C-[(L 42 ) b42 -(R 42 ) c42 ], X 43 C-[(L 43 ) b43 -(R 43 ) c43 ], and X 44 C-[(L 44 ) b44 -(R 44 ) c44 ], L7, L 11 -L 14 , L 21 -L 23 , L 31 -L 33 and L 41 -L 44 Each independently selected from phenyl groups and naphthyl groups; and A phenyl group and a naphthyl group each substituted by at least one selected from the group consisting of deuterium, C1-C 20 Alkyl, and C1-C 20 Alkoxy, b7, b31-b33 and b41-b44 are each independently 0 or 1, b11-b14 and b21-b23 are each 0, R 11 -R 14 and R 21 -R 23 Each independently selected from Hydrogen, Deuterium, C1-C 20 Alkyl, and C1-C 20 Alkoxy; Each of the following C1-C 20 Alkyl and C1-C 20 Alkoxy: deuterium, -CD3, -CD2H, -CDH2, and C1-C 10 Alkyl; and -Si(Q3)(Q4)(Q5), R 31 -R 33 and R 41 -R 44 Each independently selected from Hydrogen, Deuterium, C1-C 20 Alkyl, and C1-C 20 Alkoxy; Each of the following C1-C 20 Alkyl and C1-C 20 Alkoxy: deuterium, -CD3, -CD2H, -CDH2, and C1-C 10 alkyl; phenyl and naphthyl; phenyl and naphthyl, each substituted by at least one selected from the group consisting of deuterium, -CD3, -CD2H, -CDH2, and C1-C 10 Alkyl; and -Si(Q3)(Q4)(Q5), Selected from R 31 , R 32 , R 33 , R 41 , R 42 , R 43 and R 44 At least one of each is independently selected from phenyl and naphthyl; and phenyl and naphthyl, each substituted by at least one selected from the group consisting of deuterium, -CD3, -CD2H, -CDH2, and C1-C 10 alkyl, R7 is phenyl or naphthyl; or Each of the phenyl or naphthyl groups is selected from at least one substituted group consisting of deuterium, -CD3, -CD2H, -CDH2, C1-C 20 Alkyl, C1-C 20 Alkoxy, phenyl, naphthyl, and -Si(Q 33 )(Q 34 )(Q 35 ), Q3-Q5 and Q 33 -Q 35 Each independently selected from: -CH3, -CD3, -CD2H, -CDH2, -CH2CH3, -CH2CD3, -CH2CD2H, -CH2CDH2, -CHDCH3, -CHDCD2H, -CHDCDH2, -CHDCD3, -CD2CD3, -CD2CD2H, and -CD2CDH2; n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, and tert-pentyl; and n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, and tert-pentyl, each substituted with at least one deuterium, c7 is 1, c11-c14, c21-c23, c31-c33 and c41-c44 are each independently an integer of 1-5.

2. The organometallic compound according to claim 1, wherein R 11 and R 13 Each independently selected from: isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, sec-pentyl, tert-pentyl, isohexyl, sec-hexyl, tert-hexyl, isoheptyl, sec-heptyl, tert-heptyl, isooctyl, sec-octyl, tert-octyl, isononyl, sec-nonyl, tert-nonyl, isodecyl, sec-decyl, and tert-decyl; and each of at least one substituted isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, sec-pentyl, tert-pentyl, isohexyl, sec-hexyl, tert-hexyl, isoheptyl, sec-heptyl, tert-heptyl, isooctyl, sec-octyl, tert-octyl, isononyl, sec-nonyl, tert-nonyl, isodecyl, sec-decyl, and tert-decyl selected from the group consisting of deuterium, -CD3, -CD2H, -CDH2, C1-C 10 Alkyl, and C1-C 10 Alkoxy.

3. The organometallic compound according to claim 1, wherein R 43 or R 44 Each independently selected from: phenyl and naphthyl; and phenyl and naphthyl, each substituted by at least one selected from the group consisting of deuterium, -CD3, -CD2H, -CDH2, and C1-C 10 alkyl.

4. The organometallic compound according to claim 1, wherein R 11 -R 14 and R 21 -R 23 are each independently selected from hydrogen, deuterium, -CH3, -CD3, -CD2H, -CDH2, groups represented by formulae 9-1 to 9-19, and -Si(Q3)(Q4)(Q5), and R 31 -R 33 and R 41 -R 44 Each is independently selected from hydrogen, deuterium, -CH3, -CD3, -CD2H, -CDH2, groups represented by formulae 9-1 to 9-19, groups represented by formulae 10-13 to 10-20, 10-49 to 10-62, 10-70 to 10-72, 10-81 to 10-82, and 10-162, and -Si(Q3)(Q4)(Q5): In formulas 9-1 to 9-19, 10-13 to 10-20, 10-49 to 10-62, 10-70 to 10-72, 10-81 to 10-82, and 10-162, * indicates the binding site to the neighboring atom.

5. The organometallic compound of claim 1, wherein R7 is selected from the group represented by the formula 10-13 to 10-20, 10-42 to 10-73, 10-79 to 10-85, 10-142 to 10-145, and 10-162: In formulas 10-13 to 10-20, 10-42 to 10-73, 10-79 to 10-85, 10-142 to 10-145, and 10-162, * indicates the binding site to the neighboring atom; Ph represents phenyl; and TMS stands for trimethylsilyl. The organometallic compound as claimed in claim 1 , wherein b7 is 0.

7. The organometallic compound according to claim 1, wherein In formula 1-1, The part represented by is represented by one selected from the formulas CY1(1) to CY1(8), The part represented by is represented by one selected from the formulas CY2(1) to CY2(4), represented by The part represented by is represented by one selected from the formulas CY3(1) to CY3(5), and by The part represented by is represented by one selected from formulas CY4(1) to CY4(9): in, In formulas CY1(1) to CY1(8), Y1 is C, L1, L 1a and L 1b Each independently of claim 1 regarding L 11 Same as described, b1 is the same as described in b11 in claim 1, R1, R 1a and R 1b Each independently of the above in claim 1 regarding R 11 Same as described, c1 is the same as described in claim 1 regarding c11, *-(L1) b1 -(R1) c1 、*-(L 1a ) b1 -(R 1a ) c1 , and *-(L 1b ) b1 -(R 1b ) c1 Not hydrogen, *' represents the binding site to X1 of formula 1-1, * represents the binding site to the adjacent atom of formula 1-1, In equations CY2(1) to CY2(4), X2, X 51 , L2, b2, R2 and c2 are each independently the same as those in claim 1 with respect to X2, X 51 , L 21 ,b21,R 21 Same as described in c21, *-(L2) b2 -(R2) c2 Not hydrogen, *' represents the binding site to M of formula 1-1, * and *" each represent a binding site to an adjacent atom of formula 1-1, In formulas CY3(1) to CY3(5), X3 is the same as described in claim 1, L3, L 3a , and L 3b Each independently of claim 1 regarding L 31 Same as described, b3 is the same as described in b31 in claim 1, R3, R 3a , and R 3b Each independently of the above in claim 1 regarding R 31 Same as described, c3 is the same as described in claim 1 regarding c31, *-(L3) b3 -(R3) c3 、*-(L 3a ) b3 -(R 3a ) c3 , and *-(L 3b ) b3 -(R 3b ) c3 Not hydrogen, *' represents the binding site to M of formula 1-1, * and *" each represent a binding site to an adjacent atom of formula 1-1, In formulas CY4(1) to CY4(9), X4 is N, L4, L 4a , and L 4b Each independently of claim 1 regarding L 41 Same as described, b4 is the same as described in b41 in claim 1, R4, R 4a , and R 4b Each independently of the above in claim 1 regarding R 41 Same as described, c4 is the same as described in claim 1 regarding c41, *-(L4) b4 -(R4) c4 、*-(L 4a ) b4 -(R 4a ) c4 , and *-(L 4b ) b4 -(R 4b ) c4 Not hydrogen, *' represents the binding site to M of formula 1-1, * indicates a binding site to an adjacent atom of Formula 1-1.

8. Organic light-emitting device, comprising: a first electrode; a second electrode; as well as an organic layer between the first electrode and the second electrode, the organic layer comprising an emission layer, The organic layer comprises at least one of the organic metal compounds as described in any one of claims 1 to 7.

9. The organic light emitting device according to claim 8, wherein The first electrode is an anode, The second electrode is a cathode, The organic layer further includes a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode, The hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and The electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

10. The organic light emitting device of claim 8, wherein the emission layer comprises the organic metal compound. 11 . The organic light emitting device of claim 10 , wherein the emission layer further comprises a host, and an amount of the host in the emission layer is greater than an amount of the organometallic compound in the emission layer.

Images